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ABSTRACT 
The bioflavonoid hesperidin and its aglycone hesperetin are promising candidates for the 
treatment of diabetic retinopathy and diabetic macular edema because of their pharmacological 
properties. The objective of this project was to characterize the biopharmaceutic and 
pharmacokinetic characteristics of hesperidin and hesperetin for ocular delivery, especially with 
respect to the distribution of these compounds to the posterior segment of the eye. 
Hesperidin and hesperetin were found to be water insoluble compounds. Although they 
demonstrated good permeability across the ocular tissues, hesperetin’s permeability was found to 
be higher than that of hesperidin. Hesperidin demonstrated symmetrical transcorneal and 
transretinal permeation whereas hesperetin exhibited asymmetrical transcorneal and symmetrical 
transretinal transport. However, none of the influx or efflux transporters, expressed on the 
cornea, were involved in hesperetin’s corneal transport. It was concluded that hesperetin’s 
physicochemical properties, ultrastructure of the cornea and components of the diffusion media 
play a major role in the passive asymmetric transport.  
Results from the intravitreal kinetic studies of hesperidin, hesperetin and glucosyl-
hesperidin (a water soluble derivative of hesperidin), following intravitreal injection, revealed 
that all three compounds have relatively short half-lives (< 8h) in the vitreous humor. Hesperetin 
demonstrated the shortest half-life, consistent with its physiochemical characteristics. All three 
compounds exhibited linear pharmacokinetics, within the dose range tested. This information 
will be critical in the design of ocular drug delivery systems for these compounds. 
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The ocular bioavailability studies following systemic administration suggested that 
vitreal bioavailability is negligible because of rapid conversion of both hesperidin and hesperetin 
into their hydrophilic metabolite, hesperetin-glucuronide, in the plasma. In contrast, topical 
instillation produced significant concentrations of hesperidin and hesperetin in the ocular tissues. 
Hesperetin’s diffusion into the ocular tissues, in vivo, was high compared to hesperidin; however, 
very low levels were observed in the vitreous humor. Inclusion of benzalkonium chloride, as a 
penetration enhancer/preservative, significantly improved the vitreal levels of hesperetin. 
In conclusion, topical administration would be ideal for the delivery of hesperetin to the 
deeper ocular tissues. Development of a controlled release drug delivery system and specialized 
ophthalmic formulations will reduce the frequency of administration needed to sustain the levels 
at the target site. 
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CHAPTER 1 : OVERVIEW OF THE RESEARCH PROJECT  
 
INTRODUCTION 
Eye, the organ of sight, has a very unique structural and biochemical organization. Age 
and certain disease conditions, however, can affect the function of this vital organ. A report from 
the World Health Organization (WHO) in 2002 estimated that approximately 161 million people 
were suffering from visual impairment worldwide, out of which 37 million face blindness while 
124 million suffer from low vision. Age seems to be a causative factor in blindness as 82% of the 
population with blindness are aged above 50 years (1). In the United States, in 2002, among 
civilian non-institutionalized adults, 19.1 million people were suffering from visual impairment 
including 0.3% with blindness (2). Although, blindness is necessarily associated with ageing, the 
leading causes of blindness are cataract, refractive error, glaucoma, age-related macular 
degeneration, trachoma, childhood blindness and diabetic retinopathy (1, 3).   
With regard to diseases affecting the posterior segment of the eye, it is estimated that 
about 1.47% (1.75 million) of the population in the age group of 40 years and older in the US is 
diagnosed with AMD and this number may reach 3 million by 2020 (4). Further, approximately 
4.1 million US adults aged above 40 are suffering from diabetic retinopathy and one out of every 
12 persons with diabetes mellitus, in this age group, faces vision threatening retinopathy (5). 
Although significant progress has been made in the identification of molecular mechanisms 
involved and in the development of therapeutic agents, drug delivery to the posterior segment of 
the eye, or back-of-the eye, remains a formidable challenge for the pharmaceutical scientists.  
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Pathophysiology of diabetic retinopathy involves the process of physiological or 
pathological angiogenesis. Oxidative damage to the retinal neuronal cells as a result of free 
radical generation, a complication associated with diabetes, is considered to be a principal factor 
responsible for the initiation and progression of diabetic retinopathy (6). Decreased retinal blood 
supply, as a consequence of long term diabetes is another major contributor to the progression of 
this disease. In patients with diabetes, proliferative diabetic retinopathy is the neovascular result 
wherein ischemia induced angiogenesis on the surface of the retina, and into the vitreous, is 
postulated to occur. Increased permeability in these vessels can lead to diabetic macular edema, 
the major factor responsible for vision loss (6).  
Currently, these disorders are maintained by preventive care or treatment of the disease 
(7). Preventive care is aimed at controlling the metabolic abnormalities. Laser photocoagulation, 
vitrectomy or pharmacologic intervention, with the drugs targeting the pathophysiology of the 
disease, are the various treatment options available. However, laser photocoagulation and 
vitrectomy, which are surgical interventions, are indicated only during sight threatening 
conditions of the disease. Drugs used for treatment include, anti-inflammatory agents, anti-
VEGF agents, PKC-β inhibitors and antioxidants. However, none of these agents act on the 
multiple pathways associated with the initiation and progression of the disease.  
Hesperidin (hesperetin 7-rutinoside) is a flavanone glycoside, comprising of an aglycone, 
hesperetin, and an attached disaccharide, rutinose. Hesperidin is abundantly found in citrus fruits 
(family Rutaceae) and has also been reported to occur in many plants other than Citrus, such as 
in genera Fabaceae, Betulaceae, Laminaseae and Papilionaceae. What makes hesperidin and 
hesperetin particularly attractive for the treatment of diabetic retinopathy or macular 
degeneration is their potential effect on the ocular blood flow and vascular permeability, two 
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important factors leading to the initiation and progression of diabetic retinopathy. It has been 
demonstrated that these compounds can support retinal function recovery subsequent to retinal 
ischemia (8). Hesperidin’s effect on ocular blood vessels has not been studied. However, this 
compound was initially referred to as ‘Vitamin P’ to indicate that it  could decrease capillary 
permeability and fragility, although subsequently the term vitamin P has been discontinued (9). 
Literature suggests that these compounds can prevent microvascular leakage by virtue of their 
vasoprotective action through the inhibition of the enzyme hyaluronidase which is reported to 
regulate the permeability of capillary walls and supporting tissues (10). Additionally, it has been 
demonstrated that they can decrease blood cell and platelet aggregation, believed to be beneficial 
in cases of capillary permeability and fragility (9).  
Besides their effect on vascular permeability and ocular blood flow, both hesperidin and 
hesperetin demonstrate strong antioxidant properties (11). This antioxidant activity is through 
their ability to quench oxidative radical chain reactions (capable of oxidizing and nitrating 
cellular proteins, nucleic acids and lipids) and can thus help preserve neuronal health. These 
compounds also exhibit significant anti-inflammatory activity by modulating the prostaglandin 
synthesis and COX-2 gene expression pathways (12). Ayalasomayajula et al.,(13) reported that, 
in diabetic rat retina, up-regulation of COX-2 is responsible for the production of prostaglandin 
E2, a pro-angiogenic factor implicated in vascular permeability and leakage. This prostaglandin 
up-regulation was inhibited by celecoxib (13), a selective COX-2 inhibitor.  
Hesperidin and hesperetin has been reported to possess analgesic (14), hypolipidemic 
(15), anti-hypertensive and diuretic activity (16). Another potential therapeutic application of 
hesperidin is its anticancer activity mediated through the suppression of cell proliferation (17, 
18). Thus, both hesperidin and hesperetin appear to be capable of modulating multiple pathways 
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(Fig. 1.1) identified in the genesis and progression of diabetic retinopathy and diabetic macular 
edema. It can also be used in other ocular diseases because of its varied pharmacological actions. 
 
 
Figure 1.1: Schematic representation of some of the currently identified pathways involved in 
the development and progression of diabetic retinopathy and macular degeneration. * Indicates 
pathways which hesperidin and hesperetin can potentially inhibit. 
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STATEMENT OF THE PROBLEM 
Currently hesperidin is used as a dietary supplement for improving the blood flow and for 
its vasoprotective properties and is available as an oral dosage form. Ameer et al., (19) reported 
that following oral administration, hesperidin is absorbed across the gastrointestinal tract, but 
cumulative urinary recovery indicates low bioavailability (<25%). Several factors limit oral 
bioavailability of hesperidin, including poor water solubility and precipitation in an acidic 
environment (20). Moreover, hesperidin and hesperetin are substrates of the intestinal efflux 
protein, P-glycoprotein (P-pg), (21-23) and intestinal and hepatic drug metabolizing enzymes 
CYP450 (24). These factors, acting together, severely restrict systemic bioavailability of the 
orally administered drug. Furthermore, hesperidin possesses poor transmembrane permeability 
and is believed to be absorbed primarily by the paracellular pathway (25, 26). Thus intestinal 
tight junction proteins would limit intestinal absorption. Additionally, reports indicate that 
hesperidin needs to be converted to hesperetin, by the beta-glycosidase secreted by the intestinal 
flora (27), for absorption to occur. Thus, currently, it is unclear as to what fraction of the orally 
administered hesperidin can reach the systemic circulation. 
With respect to ocular drug delivery, the eye is a secluded organ protected by various 
physiological barriers that prevent unrestricted entry of xenobiotics into the ocular tissues from 
the external environment or systemic circulation. In case of hesperidin and hesperetin, over and 
above all the barriers to oral bioavailability, in order to exert a therapeutic effect in diabetic 
retinopathy they must reach the neural retina, the target site of action.  
In general, drug delivery to the internal ocular tissues can be achieved by topical, 
systemic or intravitreal administration routes. Delivery and maintenance of therapeutic 
concentrations by any of these routes depends on several factors: biopharmaceutic (solubility, 
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log P, pKa and permeability characteristics across the ocular barriers) and pharmacokinetic 
(absorption, distribution and elimination from ocular tissues). 
Till now no one has investigated the ocular delivery of hesperidin and its aglycone 
hesperetin through any route of administration. This research project explores two critical 
aspects in ocular delivery; biopharmaceutic (solubility, log P, pKa and permeability across ocular 
barriers) and pharmacokinetic (absorption, distribution and elimination following topical, 
systemic and intravitreal delivery) characteristics. 
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SPECIFIC OBJECTIVES 
1. Biopharmaceutic Characterization: 
i. To evaluate solubility, stability, physicochemical properties and in vitro 
permeability of hesperidin across the ocular tissues - cornea, sclera and retinal 
pigmented epithelium (RPE). 
ii. To evaluate solubility, stability, physicochemical properties and in vitro 
permeability of hesperetin across the ocular tissues - cornea, sclera and RPE. 
 
2. Pharmacokinetic Characterization: 
i. To investigate the ocular bioavailability and to simultaneously evaluate systemic 
pharmacokinetics following intravenous administration. 
ii. To investigate distribution of these compounds into the posterior segment of the eye 
following topical instillation. 
iii. To determine ocular kinetics and disposition characteristics of these molecules 
following intravitreal administration. 
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CHAPTER 2 : LITERATURE REVIEW 
 
ANATOMY OF THE EYE  
The structure of the eye can be described in terms of different tissue layers and fluid 
compartments, as comprised of (Figure 2.1).  
External layer  : Cornea and sclera, 
Intermediate layer : Iris-ciliary body, lens and choroid 
Internal layer  : Retina 
Fluid compartments : Aqueous humor and vitreous humor 
 
From a drug delivery perspective, the eye can be broadly divided into anterior and 
posterior segments. Anterior segment consists of the cornea, the conjunctiva, the iris-ciliary 
body, the lens and the aqueous humor. Posterior segment consists of the sclera, the choroid, the 
retina and the vitreous humor. 
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The following section briefly describes the anatomy of the different tissue layers and fluid 
compartments of the eye. 
Cornea 
The cornea is an optically transparent avascular tissue, which allows light to reach the 
retina. The structure of the cornea is complex and is mainly composed of five layers of tissues: 
the epithelium, the Bowman’s membrane, the stroma, the Decement’s membrane, and the 
endothelium. The epithelium is the outermost layer of the cornea and is composed of 5-6 layers 
of epithelial cells which are tightly packed together and is hydrophobic in nature, which makes it 
an important barrier to drug delivery. The Bowman’s membrane separates the epithelium and the 
stroma. The stroma comprises around 90% of the corneal thickness and is hydrophilic in nature 
because 85% of the stroma is water. The stroma acts as a barrier to the delivery of lipophilic 
compounds. The Decement’s membrane lies between the stroma and the endothelium. The 
endothelium is a monolayer in thickness with loose intercellular junctions. It is in contact with 
the aqueous humor and is responsible for controlling corneal hydration. Nutrients and oxygen to 
the corneal cells is supplied by the lachrymal fluid and aqueous humor as well as by the blood 
vessels located at the junction between the cornea and the sclera (28).  
There are two major pathways of drug penetration across the corneal epithelium, 
transcellular and paracellular. Transcellular diffusion can take place by the partitioning of the 
drug into the cell membrane or by diffusion through the cellular pores. Paracellular pathway 
involves diffusion through the intercellular space. The delivery of therapeutic agents across the 
cornea primarily depends on the physicochemical properties of the compound and on the 
involvement of any functional nutrient transporters expressed on the cornea (29, 30). 
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Sclera 
The sclera is the opaque outer tunic of the eye. It extends from the outer ring of the cornea 
to the optic foramen, and is perforated by the optic nerve. It is usually referred to as the “white of 
the eye” and is a protective layer. The scleral tissue possesses considerable viscoelastic 
properties and consists of the tenon’s capsule, the episclera, the stroma, the spur and the lamina 
fusca (31). The tenon’s capsule and the episclera are the two outermost vascularized layers of the 
sclera. The stroma is composed of collagen and elastic fibers. The lamina fusca forms the outer 
portion of the choroid and is a component of both the uveal tract and the sclera (31, 32). The spur 
is a rigid ring like structure formed by the abridgment of the deep scleral fibers with the fibers of 
the limbus. The sclera is mainly made up of collagen fibrils, predominantly Type I collagen, 
embedded in a glycosaminoglycan (GAG) matrix. In addition, collagen Types III, V, VI, VIII 
and XII are also found in the human sclera.  Based on the structure and composition of the sclera 
it is believed that hydrophilic drugs are better suited for transscleral diffusion. (32) 
Iris-ciliary body 
The iris is the opaque ring visible through the cornea, in front of the lens and is made up 
of connective tissues and muscles with a circular opening, called the pupil. Pigmentation of the 
iris gives a characteristic color to the eye. The ciliary body is a complex, highly specialized 
vascular tissue comprising of several cell types. Contraction or relaxation of the ciliary muscle 
alters the tension on the lens causing it to alter shape and thus shift focus. The surface of the 
ciliary body is elaborated into a series of ridges named ciliary processes, which are short, black 
tissues arranged radially. The ciliary body secretes the aqueous humor. In the iris-ciliary body 
there are two types of muscles, radial and circular. They change the pupil size to control the 
amount of light entering the eye. (33)  
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Choroid 
The choroid is another vascular tissue of the eye, sandwiched between the outer sclera 
and the retina. It is light to dark brown in color and continues anteriorly into the ciliary body and 
iris, and ends posteriorly at the optic nerve. The choroid is classically divided into four or five 
layers by light microscopy; the epichoroid, the vessel layer, the choriocapillary layer and the 
Bruch’s membrane. It is opaque and deeply pigmented with melanin in order to absorb excessive 
light; otherwise internal reflection would form multiple images on the retina. The principal 
functions of the choroid are to nourish the outer retina and to provide a pathway for blood 
vessels that supply the anterior part of the eye (33). The choroidal region of the eye has the 
highest per unit blood volume (34). Thus, for compounds traversing across this region, the 
choroid is considered to act as a sink because of the huge network of blood capillaries: the 
choroidal capillaries. 
Retina 
The retina is the light sensitive part of the eye and is a thin film of tissue covering most of 
the inner wall of the eye. Histologically, the retina is an extremely well‐organized tissue in which 
10 layers are classically recognized. The inner limiting membrane (ILM), a basement membrane, 
forms the boundary with the vitreous humor and the outermost layer of the retina, retinal 
pigmented epithelium (RPE). The layers in between these two layers include, the retinal nerve 
fiber layer, the ganglion cell layer, the inner plexiform layer, the inner nuclear layer, the outer 
plexiform layer, the outer nuclear layer and photoreceptor layer (33). 
The RPE, a single epithelial cell layer under the choroid, plays a vital role in the support 
and maintenance of neural retina viability. RPE cells can be differentiated into an apical portion, 
facing the neural retina, and a basolateral portion, facing the choroid. These cells are polarized 
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and express several nutrient transporters on the apical and basolateral membranes. The macula is 
the central part of the retina that provides fine central vision and color perception. The fovea is a 
depression at the center of the macula. The RPE is an important physical barrier to drug delivery 
to the posterior segment of the eye (35). 
Vitreous humor 
Vitreous humor fills the region between the lens and the retina. It occupies nearly 80% of 
the eye globe. The main component of the vitreous humor is water (98-99% w/w), with a 
microstructure of collagen and glycosaminoglycans (hyaluronan, chondroitin sulphate and 
heparin sulphate) conferring viscoelastic properties. The alignment of collagen and 
glycosaminoglycans plays a key role in the maintenance of rigidity and stability of the vitreous 
gel. Importantly, it also acts as a molecular barrier to diffusion. (33, 36)  
Aqueous humor 
Aqueous humor, a clear colorless liquid, is produced by the ciliary body by ultrafiltration. 
The production rate of aqueous humor is 2-3 µL/min and is responsible for the maintenance of 
the shape of anterior chamber and nourishment of various ocular tissues. It is slightly acidic (pH 
7.2), hypertonic and has less protein content compared to the plasma. A major function of the 
aqueous humor is maintenance of intraocular pressure (IOP) and providing nutrients (glucose, 
oxygen, electrolytes) to meet the metabolic requirements of the avascular cornea. The aqueous 
humor also aids in the elimination of metabolic products (lactate, pyruvate, carbon dioxide). 
Elimination of aqueous humor takes place via the trabecular meshwork into the canal of 
Schelmm and finally into the systemic circulation (37). 
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OCULAR DRUG DELIVERY  
Drug delivery to the eye poses significant challenges due to the presence of the unique 
anatomical and physiological barriers. Ocular drug delivery can be broadly categorized into 
anterior segment and posterior segment drug delivery. Treatment of anterior segment diseases is 
relatively less problematic compared to the posterior segment diseases. The following section 
briefly discusses various routes of administration for ocular delivery.  
 
 
Figure 2.2: Routes of drug administration to the eye 
 
Courtesy: Figure was adapted and modified from National Eye Institutes (NEI), National 
Institutes of Health (NIH). 
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Topical Route  
It is the most common and convenient method for ocular drug delivery and, importantly, 
is the most effective route for the treatment of anterior segment diseases. The corneal route 
represents the major pathway of absorption following topical administration of a medication. The 
major advantage of this route is ease of application, noninvasiveness and very little, if any, 
systemic exposure. However, only 1-7% of the instilled dose reaches the aqueous humor. Several 
factors e.g. formulation (aqueous solubility and stability) and permeability/delivery (precorneal 
drainage, corneal ultrastructure and drainage through the conjunctival vasculature or 
nasolacrimal duct) issues, limit bioavailability of the administered drug by this route (28, 38, 39). 
Systemic or Oral Administration  
These are other options for delivering therapeutic agents to the ocular tissues. However, 
these routes are challenged by physiological barriers like the blood-aqueous-barrier (BAB) and 
the blood-retinal-barrier (BRB) for the anterior and posterior ocular segments, respectively. The 
BAB is composed of two discrete cell layers located in the anterior segment of the eye, the 
endothelium of the iris-ciliary blood vessels and the nonpigmented ciliary epithelium. Both cell 
layers prevent the entry of solutes from the systemic circulation into the aqueous humor because 
of presence of the tight intercellular junctions. The BRB restricts the entry of therapeutic agents 
from the blood into the posterior segment of the eye. It is composed of two types of cells, the 
retinal capillary endothelial cells and the RPE cells known as the inner and outer blood-retinal 
barriers, respectively. Following oral or systemic administration drug can easily permeate into 
the choroid, due to its high vascularity. However, the outer BRB restricts the entry of drugs from 
the choroid to the retina, through the RPE tight junctions. Moreover, these routes are associated 
with unnecessary systemic exposure to the drug. Physicochemical properties of the compounds 
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and any specificity towards the nutrient transporters expressed on the ocular barriers plays an 
important role in drug diffusion across the BAB and BRB (28). 
Periocular Administration 
It includes subconjunctival, subtenon, retrobulbar, peribulbar and posterior juxtascleral 
routes. It is a more effective but minimally invasive route of drug administration for the posterior 
segment of the eye. The physical barriers associated with this route are the sclera, the choroid-
Bruch’s membrane, and the RPE. Following periocular administration drug can reach the 
posterior segment by three main routes; the first constitutes direct diffusion wherein the 
compound traverses across the underlying tissues into the vitreous humor. An alternative 
pathway could be absorption into the aqueous humor followed by diffusion into the vitreous 
humor. Thirdly, the drug moiety could be absorbed into the general systemic circulation, through 
the scleral, conjunctival and soft tissue vasculature and lymphatics, and could then diffuse across 
the BRB into the vitreous humor. Lee and Robinson evaluated the contribution of each of these 
three pathways and found that only the first contributes significantly to the overall vitreal 
bioavailability of the administered drug.  Although the periocular route does deliver the 
compound into the aqueous humor and the systemic circulation, the contribution of these routes 
to drug penetration into the vitreous humor is minimal (28, 35).  
Intravitreal Administration 
Unlike the periocular route, intravitreal administration delivers the drug directly into the 
vitreous humor. It is the most effective method of drug administration for posterior segment 
diseases; however it is invasive in nature. Vitreous humor acts as a diffusional barrier and is 
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dependent on various factors like molecular weight, size and lipophilicity of the administered 
compound and pathophysiological conditions. (28) 
Overall, ocular delivery of a therapeutic agent depends on the physicochemical properties 
viz. solubility, log P, pKa and molecular weight of the administered compound. Maximum 
corneal permeability was observed for compounds with log octanol-water partition coefficient 
(logP) in the range of 2-3. Thus, for efficient ocular tissue permeation, compounds should neither 
be too lipophilic nor too hydrophilic. Solubility is important in the design of the ophthalmic 
dosage forms. Tear film and corneal pH is approximately 7.4, thus percent ionized or unionized 
at this pH, depending on the drug’s pKa, will influence partitioning of the drug across the ocular 
barriers. Besides these factors interaction with membrane influx and efflux transporters and 
hydrogen bond donors/ acceptors of the molecule is another important determinant of ocular 
tissue diffusion. (39-41) 
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MICRODIALYSIS  
The unique nature of the eye presents various challenges in the development of tools for 
evaluating drug disposition. Microdialysis is an invasive sampling technique, which involves 
surgical implantation of a probe into the organ/tissue of choice. Recently, this sampling 
procedure has attracted a lot of attention and has been effectively used in characterizing 
intraocular disposition of drugs in both the anterior and posterior chambers of the eye. For 
posterior segment microdialysis, the probe is placed in close proximity to the retina in the 
vitreous humor (42, 43). Several research publications have demonstrated the utility of the 
microdialysis technique for characterizing intravitreal kinetics of drugs (42, 44-47).  
 
(A)                                                                                 (B) 
                          
 
 
Figure 2.3: Schematic drawing depicting the dialysis in an in vitro setting. The perfusion fluid 
(perfusate) enters the probe through the inlet tubing. The dialysate is transported to a microvial 
via the outlet tubing (A). Enlarged section of the same probe (B).  
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A microdialysis system consists of pump, probe, and a microvial in which the sample is 
collected (Fig 2.3). A variety of probes with different design (linear and concentric), membrane 
and shaft length combinations are available. The molecular weight cut-off of commercially 
available microdialysis probes covers a wide range of approximately 20-100 kDa. The probe 
consists of a thin dialysis tube and a semipermeable membrane at the tip of the probe. A 
perfusion fluid enters the probe through the inlet tubing at a constant flow rate, passes through 
the microdialysis probe and is then transported through the outlet tubing and collected in a 
microvial (dialysate), see Figure 2.3. In general the perfusate is an aqueous solution that mimics 
the composition of the surrounding medium (e.g. IPBS, pH 7.4). This way it prevents excessive 
movement of molecules into or out of the periprobe fluid due to osmotic differences. The 
direction of the diffusion process is dependent on the concentration gradient. While the perfusion 
fluid passes the membrane, molecules up to a certain molar mass diffuse into (recovery) or out of 
(delivery) the perfusion fluid. Thus, microdialysis can be used both for collecting a substance in 
the dialysate as well as for delivering it into the periprobe fluid. (42, 48)  
During the process of microdialysis, the probe is implanted into the tissue or other 
matrices, e.g. aqueous humor or vitreous humor. For example, in the case of vitreal microdialysis 
a concentric probe is placed in the vitreous humor and in the case of anterior chamber 
microdialysis a linear probe in place in the anterior chamber of the eye (Fig 2.4). 
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Figure 2.4: Diagrammatic representation of the microdialysis probes implanted in the anterior 
and vitreous chambers of the eye. The design of the probe in the anterior chamber is linear and in 
the vitreous humor is concentric.  
 
Courtesy: Reproduced with kind permission from Elsevier BV (Ref 42).  
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OCULAR DISEASES/DISORDERS 
The following section briefly describes the pathophysiology of various ocular diseases 
that are related to this project. 
Diabetic Retinopathy and Diabetic Macular Edema 
Diabetes is considered to be the primary causative factor in the development of diabetic 
retinopathy (DR). The disease can be broadly categorized into three stages; background DR, pre-
proliferative DR and proliferative DR (PDR). In the first stage of DR, hyperglycemia initiates 
thickening of the capillary basement membrane and causes death of pericytes that support the 
vessel wall. Following this, microaneurysms and vascular leakage takes place leading to 
blockage of retinal capillaries and induction of local hypoxia. Subsequently, endothelial cells die 
resulting in closure of capillaries and increased areas of non-perfusion. Pre-proliferative DR is 
identifiable by the areas of increased retinal hypoxia and multiple hemorrhages because of loss 
of vascular patency.  Increased areas of non-perfusion stimulates the generation of angiogenic 
factors leading to the formation of new blood vessels, a characteristic feature of PDR. 
Subsequently retinal detachment may take place causing vision loss or blindness. Hyperglycemia 
and hypoxia are the two principal factors in the initiation and progression of DR. Production of a 
variety of local agents in the ocular tissues such as vascular endothelial growth factor (VEGF), 
prostaglandins, cyclooxygenase-2 (COX-2) and nitric oxide (NO) is indicated in the process, all 
of which contribute to vascular permeability and angiogenesis. Increased permeability in these 
vessels can lead to diabetic macular edema (DME), the major factor responsible for vision loss 
(6, 49). It is also reported that oxidative stress, associated with diabetes, is responsible for the 
initiation of retinopathy (7, 50). 
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Age-Related Macular Degeneration 
Age-related macular degeneration (AMD) is another leading cause of vision impairment 
and blindness, especially in the western countries (4). The well known risk factor for AMD is 
age. Retinal tissues most affected in this disease are the photoreceptors and the RPE. There are 
two types of AMD: an atrophic form, which is associated with pigmentary changes in the macula 
without hemorrhage or scar formation, and disciform macular degeneration, which is 
characterized by exudative mound formation and sub and intra-retinal hemorrhage. However, 
leakage of vascular content from small blood vessels in the macula following breakdown of the 
blood-retinal barrier can lead to macular edema and can endanger vision. Besides age, macular 
pigmentary change, hypertension, smoking and obesity are other risk factors. Importantly, in 
AMD, like in diabetic macular edema, free radicals and reactive oxygen intermediates are 
implicated in the initiation and progression of the disease (51-53).  
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MANAGEMENT AND PREVENTION OF DR/DME: CURRENT APPROACHES 
Primary Prevention 
The management options are aimed at controlling metabolic abnormalities. Stringent 
control of glucose levels to near normal values, the tight control of high blood pressure, and the 
treatment of hyper-lipidemia can delay the appearance and thus progression of diabetic 
retinopathy by several years (54-56). Good quality diet, exercise, and weight loss, which control 
the incidence and prevalence of diabetes, can also mitigate its complications. 
Treatment  
 Two approaches are available under treatment option; non-pharmacological intervention 
and pharmacological intervention.  
Non-pharmacological Intervention 
Laser photocoagulation and vitrectomy are the non-pharmacological interventions. The 
goal of laser photocoagulation is to control the vascular leakage through a series of focal laser 
burns at leaking microaneurysms or grid laser burns in regions of diffuse breakdown of the 
blood-retinal barrier and macular areas with capillary non-perfusion. The basis of laser treatment 
is to reduce the leakage and to reduce the macular area in the inner retina that is ischemic and 
hypoxic, and perhaps to allow oxygen from the choriocapillaries to diffuse into the hypoxic inner 
retina near it. In the case of vitrectomy, primarily recommended for treating proliferative DR, 
vitreous humor is surgically removed. In this procedure, the aim is to improve vision by taking 
out any blood in or behind the vitreous and reattaching detached area of the retina. However, 
both laser photocoagulation and vitrectomy are only indicated in advanced stages of the disease 
24 
 
and are associated with an additional risk of vision loss, and neither is effective in bringing 
vision back to normal (54-57). 
Pharmacological Intervention 
The multi-factorial nature of DR and DME has made these complex diseases difficult to 
treat with the limited treatment options available, in addition to the limitations of non-
pharmacological treatment options. Currently, available treatment regimens mainly target the 
underlying biochemical mechanisms that cause DR/DME. Following are the various options 
available (7, 57, 58). 
1. Vascular Endothelial Growth Factor (VEGF) Inhibitors: Clinical studies have indicated an 
increase in the levels of VEGF in patients as they progress from non-proliferative DR to 
proliferative DR. Currently three major anti-VEGF compounds are being used for the 
management of DR/DME; bevacimuzab, pegaptanib sodium and ranibizumab. 
2. Anti-inflammatory agents: Corticosteroids are capable of reducing vascular permeability and 
blood-retinal barrier breakdown, down-regulating VEGF production and inhibiting 
inflammatory mediators. Currently, intravitreal triamcinolone acetonide, dexamethasone and 
fluocinolone acetonide are being investigated and used for the management of DR/DME. 
3. Protein Kinase C (PKC) Inhibitors: Activation of PKC-β may play a role in the pathogenesis 
of DR. Its activation regulates VEGF expression. One drug studied in this category, in 
clinical trials, is ruboxistaurin. However, its use in humans is still unknown. 
4. Antioxidants: Oxidative stress is believed to play an important role in the pathogenesis of 
DR/DME. Thus, strategies to prevent the deleterious effects of free radicals were considered 
as a potential prevention or treatment option. Several antioxidants like vitamin E, lipoic acid, 
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green tea and benfotiamine (thiamine derivative B1) were shown to be effective in animal 
models. However, outcomes of some clinical trials have been ambiguous.  
 
In summary, various treatment options discussed above act on any one of the multiple 
biochemical pathways associated with the initiation and progression of DR and DME. A 
compound that acts on multiple pathways associated would be an ideal candidate for further 
explorations. 
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HESPERIDIN AND HESPERETIN  
Structure and Chemistry  
Hesperidin (hesperetin-7-rutinoside) is a flavanone glycoside, comprising of an aglycone, 
hesperetin, and an attached disaccharide, rutinose. The structures of hesperidin and hesperetin 
are illustrated in Figure 2.5.  The rutinose (C12H22O10) is composed of one molecule each of 
rhamnose and glucose.  In hesperidin, glucose is attached to hesperetin and rhamnose is attached 
to the glucose. Hesperetin (C16H14O6) chemically is 3', 5, 7-trihydroxy-4'-methoxy flavanone. 
Hesperidin is thus 3', 5, 7-trihydroxy-4'methoxyflavanone-7-(6-α-L-rhamnopyranosyl-β-D-
glucopyranoside or -7-rutinoside (Calomme et al., 1996).  
 
 
 
 
 
Figure 2.5: Chemical structure of Hesperidin (A) and Hesperetin (B) 
 
A 
B 
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Physical Properties 
Hesperidin 
Molecular Formula : C28H34O15 
Molecular Weight : 610.57 g/mole 
Exact Mass  : 610.18977 g/mole 
Physical nature : Long hair-like needles 
Color   : Tan or pale yellow 
Taste : Tasteless (In general, rutinosides are non-bitter)  
Melting Point  : 258-262°C (softens at 250°C) 
 
Hesperetin 
Molecular Formula : C16H14O6 
Molecular Weight : 302.27 g/mole 
Exact Mass  : 302. 079038 g/mole 
Physical nature : Crystalline  
Color   : Slight yellow powder or pale yellow powder  
Melting Point  : 227-232 ˚C  
 
 
 
 
28 
 
Source 
Hesperidin is abundantly found in citrus fruits (family Rutaceae) and has also been 
reported to occur in many plants other than Citrus, such as in genera Fabaceae, Betulaceae, 
Laminaseae and Papilionaceae. Hesperidin is one of the major flavonoids found in the oranges 
and mandarins. It occurs in greatest concentration in green fruit and its concentration in the fruits 
increases on storage. Its distribution in the epicarp, mesocarp, endocarp and juice of Citrus fruits 
has been reported in the literature (9). 
Commercial Products 
In traditional medicine it is used as dietary supplement for its beneficial effects on the 
vascular system. It is used alone and also as a combination product. Some of the commercially 
available products are listed in Table 2.1 
 
Table 2.1: Commercially available products of hesperidin as a dietary supplement. 
 
Product Contents 
Diosvein Diosmin – 500mg,  Hesperidin – 100mg 
Hesperidin Hesperidin – 500mg 
Life Extension Hesperidin Complex Powder 
Natural Factors 
Hesperidin – 150mg 
Citrus Bioflavonoids powdered extract – 500mg 
Vitamin C complex Rutin and Hesperidin 
500-C Methoxyflavone Vitamin C with Hesperidin 
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Pharmacology 
The following section briefly describes various pharmacological activities of hesperidin 
and hesperetin that may be useful in the prevention or treatment of diabetic retinopathy or 
diabetic macular edema. 
Antioxidant Activity 
Generally, antioxidants act by scavenging the free radicals directly, because of their low 
redox potential (i.e. high reactivity of the hydroxyl groups) (59). A number of researchers have 
studied antioxidant activity or radical scavenging properties, both in vitro and in vivo, of 
hesperidin and hesperetin using a variety of assay systems (60-67). Findings from these studies 
indicate that both hesperidin and hesperetin possess strong antioxidant activity and also 
neuroprotective properties arising from their antioxidant characteristics. However, results from 
different assays varied considerably with respect to the effective concentration. Several studies 
however indicate that the aglycone hesperetin’s antioxidant potential is greater compared to 
hesperidin (68-71). 
Hesperidin is reported to be capable of inhibiting, in vitro, free radicals (hydroxyl, 
superoxide and nitric oxide free radicals) in a concentration dependent manner (72). In a study 
by Kalpana et al., the IC50 of the antioxidant activity was found to be 5.23 µg/mL, which was 
comparatively lower than that observed with standards like trolox and ascorbic acid. The 
antioxidant activity was attributed to the aromatic hydroxyl group present on the B ring, which 
donates hydrogen and electron to free radicals, stabilizing them and forming a relatively stable 
flavonoid radical. Balakrishnan et al., (63) reported that hesperidin treatment (25 mg/Kg BW) in 
rats improved the antioxidant status in the lungs and reversed the changes induced by nicotine 
treatment. Rao et al., (73) evaluated the antioxidant activity of hesperidin by studying its 
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potential to inhibit the DPPH radical and its superoxide anion scavenging activities and reported 
an IC50 of 11 µM. 
Hirata et al., (12) studied the free radical scavenging capabilities of hesperidin and 
hesperetin. The authors found the stoichiometric factor (the number of free radicals trapped by 
one mole of antioxidant) in the order of trolox (2.0) > hesperetin (0.8) > hesperidin (0.2) in the 2, 
2’ azobisisobutyronitrile (AIBN) system, whereas in the benzoyl peroxide (BPO) system, the 
order is hesperetin (0.9) > trolox (0.1) > hesperidin (0.0). Additionally, hesperidin and hesperetin 
showed potent inhibition of lipopolysaccharide induced expression of COX-2 gene, 
demonstrating anti-inflammatory activity. Cos et al., (74) studied hesperetin’s ability to inhibit 
ascorbate-induced microsomal lipid peroxidation and estimated IC50 of 22 µM for this inhibition. 
In a study by Aranganathan et al., (69, 75) hesperetin supplementation in the rats (20 mg/Kg 
BW) significantly improved the antioxidant defense system of the body. 
Effects on Vascular System 
a. Ocular blood flow 
A decrease in the ocular blood flow can lead to a number of diseases like glaucoma, 
diabetic retinopathy and macular degeneration (76). Literature suggests a significant effect of 
bioflavonoids on ocular blood flow (77-79). In 1996, Liu et al., reported that hesperetin was able 
to increase the blood flow in iris, ciliary body and choroid (77). Further investigations using 
different flavonoids revealed that this activity is dependent on the number of hydroxyl groups 
present in the flavones and flavanones and on the dihydrogenation of the flavone molecules (78-
80). Topical administration of hesperetin in the rabbits exhibited highest activity, among the 
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several flavonoids tested, with respect to increasing ocular blood flow. Additionally, it showed a 
marked increase in retinal function recovery following ischemic insult (79, 81). 
b. Effect on Retinal Cells 
 In a recent study, Xiaoting et al., (82) studied the effect of hesperidin on the expression 
of iNOS (inducible nitric oxide synthase) in cultured rabbit RPE cells.  Hesperidin was able 
protect the retinal cells by inhibiting nitric oxide (NO) production, through iNOS inhibition, in 
the concentration range of 10-80 µg/mL. 
c. Angiogenesis and Vascular Leakage 
Angiogenesis is the process of formation of new blood vessels and is characterized by 
early degradation of the extracellular matrix followed by migration and proliferation of the 
endothelial cells and, finally, maturation of the new blood vessels. Several factors are associated 
with the pathophysiology of angiogenesis, e.g. matrix metalloproteases (MMP-2 and MMP-9), 
and pro-angiogenic factors expressed in response to local injury, ischemia or inflammation, such 
as hypoxia-inducible factor-1α (HIF-1α), epidermal growth factor (EGF), vascular endothelial 
growth factor (VEGF), tumor necrosis factor-α (TNF-α), and interleukin-1, 6 and 8 and others 
(83, 84). The newly formed blood vessels are leaky in nature and this hyper-permeability causes 
interstitial edema, which leads to physical compression of the capillaries resulting in a no-reflow 
phenomenon. Retinal vascular hyper-permeability is observed in the later stages of diabetic 
retinopathy and age related macular degeneration (53). Thus, treatment with agents capable of 
decreasing capillary hyper-permeability and inhibiting angiogenesis is highly desired. Hesperidin 
and hesperetin have been reported to exhibit these properties by inhibiting various mediators 
associated with angiogenesis and thus hyper-permeability.  
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A study by Choi et al., (85) demonstrates hesperetin’s (1-100 µM) anti-angiogenic 
activity through the inhibition of the expression of PECAM-1 (platelet-endothelial cell adhesion 
molecule-1), a cell adhesion molecule, which has been implicated in vasculogenesis and 
angiogenesis. In another study by Calderone et al., (86) on the vasorelaxing effects of flavonoids, 
hesperetin showed a strong vasorelaxing effect and hesperidin exhibited a partial effect among 
the several flavonoids tested. Hesperetin was found to be acting through calcium activated 
potassium channels. 
Furthermore, recently, it has been reported that hesperidin (at concentrations of 10 and 
100 µM) is capable of inhibiting the expression of HIF-1α and inflammatory cytokine production 
in the human mast cell line (HMC-1) in addition to inhibition of TNF-α. HIF-1α an important 
mediator of inflammatory response, and one of the major transcriptional activators of VEGF 
gene expression, plays a critical role in the process of angiogenesis (87). 
The micronized purified flavonoid fraction (Daflon® 500mg) (MPFF) and its individual 
flavonoid components (diosmin, hesperidin, linarin, and isorhoifolin) were evaluated for their 
anti-leakage effect in a hamster cheek pouch animal model, where hyper-permeability was 
induced by ischemia-reperfusion. The activity displayed by hesperidin, linarin, and isorhoifolin 
was similar to or greater than that of diosmin, the major component (90%) of MPFF. MPFF 
activity was greater than that of any single flavonoid, indicating synergetic activity (88).  
Few other reports also substantiate activity of hesperetin and hesperidin on various pro-
angiogenic factors (89-91).  
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d. Ischemia/Reperfusion (IR) 
Ischemia reperfusion is capable of generating reactive oxygen species (ROS), which can 
induce arrhythmia. In a study by Gandhi et al.,(92) hesperidin effectively reduced tissue levels of 
the antioxidant enzymes like SOD, CAT, and GSH and also reduced tissue MDA levels in a rat 
model of IR induced myocardial injury. Additionally, hesperidin, by prolonging the QTc interval 
action potential duration, and subsequent refractoriness, improved IR-induced arrhythmia. 
e. Other Vascular Effects: 
In a recent 4 week clinical trial with healthy human volunteers undertaken by Morand et 
al., (93), oral consumption of orange juice or pure hesperidin (292 mg) significantly decreased 
the diastolic blood pressure and increased endothelium-dependent microvascular reactivity. This 
was speculated to be because of the positive effects of hesperidin on the cyclooxygenase 
pathway. 
Anti-inflammatory Activity 
Some of the mediators that are activated in certain inflammatory conditions are nitric 
oxide (NO), prostanoids and leukotrienes, cytokines and adhesion molecules (94). NO is 
produced from L-arginine by three nitric oxide synthase (NOS) enzymes; endothelial NOS 
(eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS). The iNOS is responsible for the 
production of larger amounts of NO for longer durations. Prostanoids and luekotrienes are also 
involved in inflammation. Prostaglandins and thromboxan A2 are produced by the 
cyclooxygenases (COX-1, COX-2 and COX-3). Generally COX-1 is expressed in most tissues 
(acts in response to hormones and other stimuli) whereas COX-2 is highly expressed in 
inflammatory cells. Leukotrienes are generated by lipooxygenases (LOX) and 5- and 12-LOXs 
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are associated with the inflammatory processes. Moreover, different cytokines are involved in 
inflammation and can be pro-inflammatory (interleukins; IL-1β, IL-2, IL-6, IFN-γ or TNF-α) or 
anti-inflammatory (IL-10, TGF-β).  Adhesion molecules also play a role in inflammation. Blood 
vessel endothelial cells characteristically respond to pro-inflammatory stimuli and recruit 
leukocytes by selectively expressing adhesion molecules on the surface, such as vascular cell 
adhesion molecules (VCAM-1), intercellular adhesion molecules (ICAM-1) and endothelial cell 
selectin (E-selectin) (94). Hesperidin/hesperetin can act on multiple pathways in the 
inflammation process as summarized in Table 2.2. Additionally several reports also document 
the anti-inflammatory activity of hesperidin and/or hesperetin, in vivo (95, 96). 
Table 2.2: General mechanisms by which hesperidin/hesperetin exert their anti-inflammatory 
activity. 
Inhibition of iNOS expression Hesperidin (97) 
Inhibition of COX-2 expression  Hesperidin (12, 97); Hesperetin (12) 
Inhibition of VCAM-1 Hesperidin (98) 
Inhibition of IL-1β Hesperetin (91) 
 
 
 
From the above discussion it is apparent that both hesperidin and hesperetin appear to act 
on the multiple pathways associated with the initiation and progression of DR and DME. 
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CHAPTER 3 : SOLUBILITY, STABILITY, PHYSICOCHEMICAL 
CHARACTERISTICS AND IN VITRO OCULAR TISSUE PERMEABILITY 
OF HESPERIDIN 
 
ABSTRACT 
The aim of this study, constituting the first step towards efficient ocular delivery of 
hesperidin, was to determine its physicochemical properties and in vitro ocular tissue 
permeability. Aqueous solubility and stability were investigated as a function pH following 
standard protocols. Permeability of hesperidin across excised rabbit cornea, sclera, and sclera 
plus retinal pigmented epithelium (RPE) was determined using a side-bi-side diffusion apparatus. 
Hesperidin demonstrated poor, pH independent, aqueous solubility. Solubility improved 
dramatically in the presence of 2-hydroxypropyl-beta-cyclodextrin (HP-β-CD) and the results 
supported 1:1 complex formation. Solutions were stable in the pH and temperature (25, 40 ºC) 
conditions tested, except for samples stored at pH 9. Transcorneal permeability in the apical-
basal and basal-apical directions was 1.11±0.86x10-6 and 1.16±0.05x10-6 cm/s, respectively. The 
scleral tissue was more permeable (10.2±2.1x10-6 cm/s). However, permeability across 
sclera/choroid/RPE in the sclera to retina and retina to sclera direction was 0.82±0.69x10-6, 
1.52±0.78x10-6 cm/s, respectively, demonstrating the barrier properties of the RPE. Our results 
suggest that stable ophthalmic solutions of hesperidin can be prepared and that hesperidin can 
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efficiently permeate across the corneal tissue. Further investigation into its penetration into the 
back-of-the eye ocular tissues is warranted. 
 
INTRODUCTION 
For a topically administered drug, penetration into the posterior chamber tissues, such as 
the RPE, may be through corneal or noncorneal routes. Transcorneal absorption represents the 
major route of penetration for most therapeutic agents. However, several studies demonstrate that 
the noncorneal route is also a significant pathway, wherein the drug molecule is supposed to 
penetrate into the intraocular tissues via diffusion across the conjunctiva and sclera (99). 
Physicochemical properties and permeability across the ocular tissues are important 
characteristics that need to be determined for any compound targeted for ocular delivery. This in 
vitro information obtained from these studies will be the starting step in understanding the 
behavior of the compound upon in vivo administration and also helps in the design of dosage 
form. 
Thus, the objective of this project, constituting the first step towards efficient ocular 
delivery of hesperidin, was to determine hesperidin’s solubility, stability, physicochemical 
properties and in vitro permeability across the ocular tissues - cornea, sclera and RPE.  
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MATERIALS AND METHODS 
Materials 
Hesperidin, hesperetin and 2-hydroxypropyl beta cyclodextrin (HP-β-CD) (1300 MW 0.6 
substitution) were purchased from Sigma-Aldrich (St. Louis, MO, USA). [14C]Mannitol was 
purchased from American Radiolabelled Chemicals Inc. (St. Louis, MO, USA) and 
[3H]diazepam was obtained from PerkinElmer Life and Analytical Sciences (Boston, MA, USA). 
All other chemicals and solvents were obtained from Fisher Scientific, USA. 
Ocular Tissues 
Ocular tissues were isolated from euthanized adult male New Zealand albino rabbits 
weighing between 2-2.5 kg (Myrtle’s Rabbitry, Thompson Station, TN, USA). Experiments 
using rabbits conformed to the tenets of the Association for Research in Vision and 
Ophthalmology statement on the Use of Animals in Ophthalmic and Vision Research and 
followed the University of Mississippi Institutional Animal Care and Use Committee approved 
protocol (07-024). Each experiment was conducted at least in quadruplicates. 
Solubility Studies 
Aqueous solubility of hesperidin was determined following standard shake flask method 
wherein excess quantity of drug was added to 5mL of solvent in a tightly capped glass vial. To 
achieve uniform mixing, samples were constantly agitated at 75 rpm at room temperature (25 ºC) 
for 24 h in a reciprocating water bath (Fisher Scientific, USA). At the end of 24h, samples were 
centrifuged (accuSpin 17R, Fisher Scientific, USA) and the supernatant was analyzed for drug 
content. Solubility was determined in water and in buffers with pH values ranging between 1.2 
and 9. Additionally, effect of surfactants and HP-β-CD on the solubility of hesperidin, was also 
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evaluated. HP-β-CD concentrations used for the phase solubility studies were 1, 2.5, 5, 7.5, 10, 
15 and 20 %w/v in water.   
Differential Scanning Calorimetry (DSC) Studies 
DSC analysis of hesperidin, HP-β-CD, physical mixture of hesperidin and HP-β-CD (1:1 
molar ratio) and the complex were carried out using a Diamond Differential Scanning 
Calorimeter (PerkinElmer Life and Analytical Sciences, Shelton, CT, USA). Samples, 2-3 mg, 
were heated in hermetically sealed aluminum pans at a heating rate of 10 °C/min (25-280 °C 
range) under a nitrogen atmosphere (flow rate 20 mL/min). An empty aluminum pan was used as 
the reference.  
Fourier Transform Infrared Spectroscopy (FTIR) Studies 
FTIR spectra were obtained using a Perkin Elmer FTIR spectrometer (PerkinElmer Life 
and Analytical Sciences, Shelton, CT, USA). Samples were mixed with dry crystalline KBr in a 
1:100 (sample: KBr) ratio and pellets were prepared. A spectrum was collected for each sample 
within the wave number region 4000-400 cm-1. 
LogP  
Predicted value of LogP was obtained using the ACD/I-Lab web service (ACD/LogP 
8.02). 
pH Stability 
Solution stability of hesperidin was determined at various pH (1.2, 3, 5, 7.4, and 9) and 
temperature (25 and 40 ºC) conditions. Buffers were prepared according to USP. Stability studies 
were initiated with the addition of 25 µL of a 1 mg/mL hesperidin stock solution to 5mL of the 
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respective buffer previously equilibrated to either 25 or 40 ºC. Aliquots (200 µL) were collected 
at 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 14, 30 and 60 days and were stored at -80 ºC until further analysis. 
Samples were analyzed using HPLC technique as described under the analytical method section.  
Stability in Ocular Tissue Homogenates 
Ocular tissues isolated from New Zealand albino rabbits were used for the metabolism 
studies. Animals were euthanized with an overdose of pentobarbital administered through the 
marginal ear vein. Eyes were enucleated immediately and washed with ice-cold Dulbecco’s 
Phosphate Buffered Saline (DPBS pH 7.4) to remove traces of blood. Vitreous humor was 
collected through an incision in the sclera. Sclera was isolated with the retinal pigmented 
epithelium (RPE) attached. The RPE/choroid section was then carefully separated from 
underlying sclera. This procedure takes approximately 10-15 min. The pooled RPE/choroid 
tissue was homogenized (TISSUMISER, Fisher Scientific, USA) in 2 mL ice-cold Isotonic 
Phosphate Buffer Saline (IPBS), pH 7.4, and then centrifuged at 4ºC (accuSpin 17R, Fisher 
Scientific, USA). Supernatant was collected and estimated for total protein content by the 
method of Bradford (Sigma - Aldrich, USA) (100). Final protein concentration was adjusted to 
1mg/mL by diluting with IPBS and used for the hydrolysis studies. Vitreous humor was used as 
such without any dilution or homogenization.  
Reactions were initiated by adding 20 µL of drug solution (1 mg/mL) to 2mL of the 
supernatant. The reactions were carried out in a water bath at 37ºC. Samples (100 µL) were 
withdrawn at predetermined time intervals and the enzymatic degradation process was arrested 
with the addition of an equal volume of ice-cold methanol:acetonitrile mixture (60:40). Rate of 
hydrolysis in IPBS pH 7.4 at 37 ºC was used as a control. Samples were analyzed using an HPLC 
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technique as described under the analytical method section. Experiments were carried out in 
triplicate.  
Corneal Permeation Studies 
Permeation of hesperidin was studied using a side-bi-side diffusion apparatus 
(PermeGear, Inc.). Corneas isolated from New Zealand Albino male rabbits were used for these 
studies. Rabbits were euthanized, and eyes were collected as described earlier. Cornea was 
isolated with a ring of sclera around it, which helps in mounting between diffusion cells. Corneas 
were washed in DPBS and mounted on the side-bi-side diffusion apparatus (standard 9 mm cells 
were used) (Fig. 3.1A) with the epithelial side facing the donor cell for apical to basolateral 
transport (A-B), and with the endothelial side facing the donor cell for basolateral to apical 
transport (B-A). Temperature of the cells was maintained at 34 ºC with the help of a circulating 
water bath. In all cases, 3 mL of transport buffer (DPBS containing 5 % HP-β-CD) or drug 
solution (150 µM of hesperidin in DPBS with 5 % HP-β-CD) was added to the apical side of the 
cornea while 3.2 mL was added to the basal side, to maintain the natural hydrostatic pressure. 
Aliquots (200 µL) were removed at predetermined time points (15, 30, 45, 60, 90, 120, 150 and 
180 min) from the receiver side and the volume withdrawn was replaced with an equal volume of 
transport buffer. Samples were stored at -80ºC until further analysis.  
Similar procedures were followed to determine transcorneal permeability of 
[14C]mannitol (55mCi/mmol) and [3H]diazepam (70Ci/mmol), both at 0.5 µCi/mL concentration. 
Five milliliters of scintillation cocktail (Fisher Scientific, USA) was added to each sample and 
radioactivity was measured using Liquid Scintillation Analyzer (PerkinElmer Life and Analytical 
Sciences, Model Tri-Carb 2900TR, Shelton, CT, USA). 
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Figure 3.1: Illustration depicting mounting of ocular tissue on regular side-bi-side diffusion cells 
(A) and on Valia-Chein Side-bi-Side diffusion cells (B) 
 
Permeation across Sclera and Retinal Pigmented Epithelium (RPE) 
Transscleral permeation studies were carried out using the 5mm diameter Valia-Chein 
side-bi-side diffusion cells from PermeGear, Inc. (Fig. 3.1B). After carefully isolating sclera 
alone, or sclera with RPE/choroid, the tissues were mounted in a manner such that outer surface 
of the sclera, known as the episclera, faced the donor side (Fig. 1B; half-cell a) and the inner side 
of sclera, or the RPE side, faced the receiver chamber (Fig.1B half-cell b) for the transport 
studies in the sclera to choroid/RPE direction (S to R direction). Donor solution was added to the 
RPE/choroid side (Fig.1B half-cell b) for transport in the RPE/choroid to scleral direction (R to S 
direction). Temperature of the cells was maintained at 37ºC with the help of a circulating water 
bath. 150 µM of hesperidin in DPBS with 5 % HP-β-CD was placed in donor chamber and 
DPBS with 5 % HP-β-CD was placed in receiver chamber. Aliquots (200 µL) were removed at 
predetermined time points (15, 30, 45, 60, 90, 120, 150 and 180 min) from the receiver side and 
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replaced with an equal volume of transport buffer. Samples were stored at -80ºC until further 
analysis.  
Similar procedures were followed to determine permeability of [14C]mannitol (55 
mCi/mmol) and [3H]diazepam (70 Ci/mmol), both at 0.5 µCi/mL concentration, across 
sclera/choroid/RPE. Five milliliters of scintillation cocktail (Fisher Scientific, USA) was added 
to each sample and radioactivity was measured using Liquid Scintillation Analyzer. 
 
Analytical Method 
Hesperidin content in samples collected from the solubility, stability and permeability 
studies was estimated using an analytical method based on reversed phase HPLC. An HPLC 
system equipped with Waters 600 pump controller, 2470 dual wavelength UV detector, 
refrigerated 717 plus auto-sampler and Agilent 3394B integrator was used. The detector was 
operated at 284nm. Mobile phase consisted of 20mM monobasic potassium phosphate (pH 
adjusted to 2.5 with orthophosphoric acid) and acetonitrile in a ratio of 75:25 and flow rate was 
maintained at 1mL/min. A Waters Symmetry Shield C18 column was used.  
Analytical method for the determination of hesperetin content was also developed. The 
method for hesperetin was similar to that for hesperidin, except for the mobile phase, which, in 
this case, was a 50:50 mixture of acetonitrile and 20mM monobasic potassium phosphate (pH 
adjusted to 2.5 with orthophosphoric acid). 
 
Data Analysis 
Cumulative amount (Mn) transported was calculated using Equation 1 and Steady state 
(SS) fluxes (µg/min/cm2) were determined from the slope of the cumulative amount of drug 
transported vs. time graph and expressed as per unit of surface area as described by Equation 2. 
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Where, Mn is the cumulative amount of the drug in the receiver chamber at nth sampling 
time point (n=1, 2, 3, 4, 5, 6, 7 and 8 corresponding to 15, 30, 45, 60, 90, 120, 150 and 180 min 
sampling points), Vr is the volume of the medium in the receiver chamber, VS is the volume of 
the sample withdrawn at the nth time point, Cr(n) is the concentration of the drug in the receiver 
chamber medium at nth time point, A is the surface area of the tissue exposed to the permeant 
(surface area of cornea and sclera/RPE exposed is 0.636 and 0.192  cm2, respectively). Note that 
when n=1, the second part of the right hand side of Equation 1 becomes zero since concentration 
in the receiver chamber, Cr, is zero at time zero. 
Membrane permeability (cm/s) values were determined by normalizing the steady state 
fluxes to the donor concentration, Cd according to Equation (3). 
Permeability (Papp) = Flux/Cd    (Eq. 3) 
All experiments were carried out at least in triplicate. Unpaired t-test and ANOVA was 
used for statistical analysis. In all the cases a p value less than 0.05 was considered to denote 
statistically significant difference. 
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RESULTS AND DISCUSSION 
Diabetic retinopathy and macular edema are serious sight threatening conditions. While 
involvement of several mechanisms in the pathogenesis of this disease has been suggested, a 
drug candidate capable of blocking multiple pathways remains to be identified, as yet. Current 
treatment options, apart from controlling blood glucose and lipid levels, include corticosteroids, 
anti-vascular endothelial growth factor, laser photocoagulation, and vitrectomy. However, long 
term treatment with these drugs is associated with toxicity and corticosteroids may lead to 
cataract formation and increased intraocular pressure (101). Hesperidin appears to modulate 
multiple pathways associated with diabetic retinopathy and macular edema but a suitable ocular 
delivery mechanism is lacking. In this study, feasibility of developing an ophthalmic solution 
dosage form of hesperidin was investigated 
Solubility is an important factor affecting drug permeability across biological 
membranes. Solubility of hesperidin in different pH buffers and in water is presented in Table 
3.1. The compound was observed to be very poorly soluble in water and exhibited an aqueous 
solubility value of 4.95 µg/mL (7.5x10-6 M) at 25 °C. Hesperidin did not demonstrate pH 
dependent solubility within the pH range of 1.2 – 9. However, solubility of hesperidin at pH 
values greater than 9 was significantly higher (data not shown) but was accompanied with 
degradation. These results are in agreement with the studies reported by Serra et al., wherein the 
pKa of hesperidin has been reported to be 10±0.2 for the two phenolic hydroxyl groups and 
greater than 11.5 for all of the alcoholic hydroxyl groups (26). 
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Table 3.1: Solubility of hesperidin as a function of pH (200 mM buffer concentration) and in 
water. The solubility studies were carried out at 25ºC for a period of 24h.  Values are expressed 
as mean ± SD (n=3). 
 
pH Saturation Solubility (µg/mL) 
1.21 4.15 ± 0.34 
3.11 8.44 ± 0.47 
5.12 5.96 ± 1.92 
7.48 5.26 ± 0.31 
9.11 8.93 ± 0.73 
Water 4.93 ± 0.99 
 
 
In an attempt to improve hesperidin’s aqueous solubility, effect of ethanol, surfactants 
and HP-β-CD, was evaluated. Ethanol and surfactants such as Tween 80 and TPGS (d-alpha-
tocopheryl polyethylene glycol 1000 succinate) were ineffective. However, HP-β-CD markedly 
improved hesperidin’s solubility. Cyclodextrins are a group of cyclic oligosaccharides that have 
been shown to improve solubility of a multitude of poorly soluble compounds, through the 
formation of inclusion complexes. Among the different cyclodextrins available, HP-β-CD has 
been reported to be safe for use in ocular preparations (102, 103), even when used at 
concentrations as high as 45 % (104).  
A linear increase in aqueous solubility of hesperidin was observed with increasing 
concentrations of HP-β-CD (Fig. 3.2 and Table 2.2) suggesting formation of a 1:1 inclusion 
complex between hesperidin and HP-β-CD. It is interesting to note that hesperidin’s solubility 
was increased approximately 100-fold in the presence of 20 % HP-β-CD. The solubility limit of 
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the complex was not reached within the concentration range of HP-β-CD used in this study. 
Stoichiometry, binding constant (K) and aqueous saturation solubility (S0) were determined from 
a plot of solubility as a function of HP-β-CD concentration using Equation 4, according to the 
method proposed by Higuchi and Connors. Hesperidin binding constant was calculated to be 
625±78 M-1 (R2=0.975±0.023, slope=0.0052±0.0006).  
Slope)(1S
Slope
K
0 −
=
  (Eq. 4) 
Further evidence of the formation of an inclusion complex was obtained from thermal 
and spectral analysis. The DSC thermograms are presented in Figure 3.3. DSC scans of pure 
hesperidin showed an endothermic peak at 259 °C, corresponding to the melting point of the 
compound. Physical mixture of the drug and HP-β-CD, in a 1:1 molar ratio, also exhibited the 
endothermic peak associated with hesperidin. However, the peak was not observed in the 
complex, prepared by dissolving both the components in methanol (1:1 molar ratio) followed by 
evaporation. This suggests molecular encapsulation of drug inside the cyclodextrin cavity. FTIR 
scans complemented the DSC data (Fig. 3.4). Hesperidin spectra demonstrate a strong absorption 
band at 1644 cm-1, corresponding to its carbonyl stretching vibration. This characteristic 
carbonyl stretching vibration was shifted to 1652 cm-1 in the complex and was much broader, 
suggesting the formation of complex. Thus, chemical, thermal and spectral analysis, taken 
together, strongly supports the formation of an inclusion complex. 
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Table 3.2: Aqueous solubility of hesperidin (25°C, 24h equilibration) in the presence of various 
concentrations of HP-β-CD. Values are expressed as mean ± SD (n=3). 
 
Concentration of 
HP-β-CD (%w/v) 
Hesperidin Solubility 
(µg/mL) 
Fold Increase in 
solubility 
0 4.95 ± 0.99   
1 42.97 ± 4.28 9 
2.5 83.34 ± 6.34 18 
5 169.90 ± 25.36 37 
7.5 219.03 ± 15.62 48 
10 252.77 ± 8.81 55 
15 348.55 ± 5.28 76 
20 431.97 ± 0.43 95 
 
 
 
 
 
 
Figure 3.2: Phase solubility of hesperidin in the presence of HP-β-CD, at 25ºC, following 24h 
equilibration. Values are expressed as mean ± SD (n=3) 
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Figure 3.3: DSC thermograms of the pure hesperidin and HP-β-CD, physical mixture of 
hesperidin and HP-β-CD (1:1 molar ratio) and the complex. 
 
 
 
Figure 3.4: FTIR spectra of the HP-β-CD, hesperidin and the complex. 
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Phase solubility studies pointed towards the formation of the complex in a 1:1 molar 
ratio, which is consistent with an earlier report by Tommasini et al., (105). However, the 
observed intrinsic solubility of hesperidin (7.5x10-6 M) in the current study was less than the 
value (3.6x10-5 M) reported by Tommasini et al., Also, the estimated binding constant in the 
previous study was 60 M-1. The observed differences, between the earlier report and the current 
study, with respect to these two parameters, may be attributed to the experiment protocol. While 
Tommasini et al., sonicated the excess drug containing cyclodextrin solution for a period of 
15min and then allowed equilibration for a period of 4 days, in the current study sonication was 
not a part of the protocol and equilibration period allowed was only 24 h. 
Hesperidin, a flavonoid glycoside, can be converted into its aglycone, hesperetin, through 
chemical or enzymatic processes. Stability studies in aqueous solutions did not demonstrate any 
decrease in hesperidin content up to 2 months, the final time point tested, in the pH range and 
temperature conditions employed. The only exception was pH 9 samples. In this case, 
degradation rate constant and half-lives, at 25 and 40°C were observed to be 0.03 and 0.15 day-1, 
and, 23 and 4.5 days, respectively (Fig. 3.5). This signifies that hesperidin may undergo alkaline 
hydrolysis at higher pH and temperature conditions.  
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Figure 3.5: Stability of hesperidin in pH 9 buffer at 40ºC. Values are expressed as mean ± SD 
(n=3) 
 
Hesperidin undergoes enzymatic degradation by beta-glucosidases to yield hesperetin. 
Literature reports suggest that beta-glucosidases are expressed in the ocular tissues, especially in 
the RPE (106, 107). Ideally, one would like to maintain the drug in the unmetabolized form at 
the target tissue for maximizing therapeutic effect. With respect to hesperidin, however, both 
hesperidin and its aglycone hesperetin are pharmacologically active. Even then, it is important to 
know the rate of generation of hesperetin, from hesperidin, in the ocular tissues as the two 
compounds would exhibit different pharmacokinetic profiles. For example, hesperetin is more 
lipophilic than hesperidin and is known to be a much better substrate of the efflux protein P-gp, 
which is also known to be expressed on the RPE (108). Consequently, conversion of hesperidin 
to hesperetin may impact therapeutic activity. Taking this into consideration, stability of 
hesperidin in ocular tissue homogenates was determined. Hesperetin generation, or decrease in 
hesperidin concentrations, in the homogenates was not observed even after 15h. Further studies 
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investigating generation of hesperetin in the ocular tissues in vivo, and their in vivo 
pharmacokinetic profile following topical and intravitreal administration, are in progress. 
Oral hesperidin administration for ocular indications may not be very effective.  Local 
delivery of hesperidin for ocular diseases may prove to be a much more viable option, compared 
to oral administration. To our knowledge, hitherto, permeability of hesperidin across ocular 
tissues has not been determined. In this study, ocular tissues isolated from New Zealand albino 
rabbits, a model widely used for ophthalmic drug delivery studies, were used to evaluate 
feasibility of penetration of hesperidin into the back-of-the eye following topical administration. 
The predicted Log P value of hesperidin was determined to be 1.78±0.72 using ACD/I-Lab 
software, which indicated that the compound is fairly lipophilic. Diffusion studies were carried 
out for 3h, to determine in vitro permeability coefficients across cornea, sclera and 
sclera/choroid/RPE. Stability studies of hesperidin in aqueous buffered solutions and tissue 
homogenates demonstrated that drug was stable in these matrices for the entire duration of the 
diffusion experiments. Since hesperidin demonstrates poor aqueous solubility, 5% HP-β-CD was 
incorporated in the transport buffer.  
Trans-epithelial electrical resistance (TEER) was monitored (Multimeter, Agilent 
Technologies, USA) throughout the duration of the corneal permeation studies, 3h, to evaluate 
the integrity of tissue in the presence of 5 % HP-β-CD. TEER values for corneas exposed to 
transport buffers with or without HP-β-CD were found to be 5±0.3 KΩcm2 throughout, 
demonstrating lack of any effect of HP-β-CD on ocular tissue integrity at this concentration. The 
observed TEER is in agreement with previously reported TEER values for rabbit cornea (109). 
In addition, diffusion of [14C]mannitol, a paracellular marker, and [3H]diazepam, a transcellular 
marker, were also evaluated. The mean percent cumulative amount of the [14C]mannitol 
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transported per hour across the cornea remained the same, for the duration of the experiment at 
1±0.15. In case of diazepam also, mean percent cumulative amount of [3H]diazepam transported 
per hour across the cornea remained steady at 1.62±0.04. These results taken together, 
demonstrate that integrity and viability of the corneal tissues are maintained during the 
experimental protocol. 
Mean cumulative amount of hesperidin transported across ocular tissues as a function of 
time is depicted in Figure 3.6 and the permeability coefficients have been presented in Figure 
3.7. Steady state diffusion was achieved within 5min. Less than 2 % decrease in hesperidin 
concentration in the donor solution was observed during the total time course of the experiments 
signifying maintenance of sink conditions. 
Hesperidin’s permeability across the rabbit cornea was 1.11±0.86x10-6 cm/s consistent 
with other compounds with similar LogP values (110).  Although, P-gp has been reported to play 
an important role in transcorneal drug absorption (108), corneal permeability of hesperidin in the 
apical to basolateral (A-B; 1.11±0.86x10-6 cm/s) and basolateral to apical (B-A; 1.16±0.05x10-6 
cm/s) directions did not differ statistically, indicating lack of involvement of any carrier-
mediated process (efflux or influx) in the corneal permeation process, at the concentration 
studied. These results are consistent with an earlier study by Kobayashi et al., (25) with Caco-2 
cell monolayers demonstrating similar hesperidin permeability in the A-B and B-A directions. 
The authors concluded that hesperidin permeates through paracellular route and absence of 
active transport process. Moreover, hesperidin behaves as a neutral molecule in the pH range of 
1-10 (26) indicating lack of involvement of any anion or cation transporters.  
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Figure 3.6: Mean cumulative amount of hesperidin transported across ocular tissues as a 
function of time. Values are expressed as mean ± SD (n=4) 
 
Transport studies across sclera and sclera/choroid/RPE were carried out using Valia-
Chein cells (PermeGear, Inc. USA). To our knowledge, these cells are being adapted for 
studying permeability across the RPE for the first time. The scleral tissue tends to fold-up into its 
natural elliptical shape while mounting on the regular flat face cells. This creates mounting 
problems, especially the risk of damaging the RPE layer.  On the other hand, it is very easy to 
mount the sclera/choroid/RPE tissue on the Valia-Chein cells. To check the validity of the new 
experimental set up, acyclovir (ACV) transport across sclera with RPE was carried out from the 
S to R (sclera to RPE) direction. The observed permeability was 2.5x10-6 cm/s. Although there 
are no prior reports for trans-RPE permeability of ACV, Kansara et al., (111) reported that the 
permeability of ganciclovir (GCV) in the S to R direction was 1.61x10-6 cm/s. GCV and ACV 
are very similar structurally, and with respect to their physicochemical characteristics. Moreover, 
the permeability of ACV and GCV across the rabbit cornea are reported to be very similar 
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(3.5x10-6 and 4.1x10-6 cm/s, respectively) (112, 113), indicating that their membrane permeation 
characteristics are also comparable. The close approximation of the permeability of ACV 
obtained using the Valia-Chien cells with that of GCV in the Franz diffusion cells, indicate that 
the RPE structure was intact during the experimental protocol. Moreover, The mean percent 
cumulative amount of  [14C]mannitol and [3H]diazepam transported per hour across the 
sclera/choroid/RPE tissues were 0.1±0.04 and 0.08±0.02, respectively, similar to the values 
reported by Kansara et al., (111). The above results indicate that sclera/choroid/RPE tissue 
maintains its integrity during the experimental protocol. 
Permeability of hesperidin across the sclera alone (10.2±2.1x10-6 cm/s) was almost 10-
fold higher than that across sclera with RPE (Fig. 3.6 and 3.7) and that across the cornea. These 
results thus substantiate the concept that RPE presents a significant barrier to the transscleral 
diffusion process following systemic as well as topical administration. However, topical 
instillation should generate significantly higher concentration gradients across the RPE and thus 
higher retinal hesperidin concentrations. 
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Figure 3.7: Permeability (cm/s) of hesperidin across various ocular tissues. A-B denotes 
permeation in the apical to basolateral direction. S-R and R-S denotes permeation in the sclera to 
RPE direction and RPE to sclera direction. Values are expressed as mean ± SD (n=4). 
 
 
The barrier properties of the RPE may be as a result of efflux pump involvement or high 
lipophilicity of the therapeutic agent. The RPE is reported to express P-gp (108), which can 
modulate drug clearance from the vitreous humor. To delineate the role of efflux mechanisms on 
trans-RPE drug delivery, permeability of hesperidin across RPE in both directions i.e. 
sclera→choroid→RPE (S-R) and RPE→choroid→sclera (R-S) was measured and were found to 
be 0.82±0.68x10-6 cm/s and 1.52±0.78x10-6 cm/s, respectively (Fig. 3.6 and 3.7). The difference 
in permeability in the S-R and R-S directions, under the experimental conditions employed, was 
statistically insignificant suggesting lack of any efflux mechanism. 
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CONCLUSION 
In conclusion, results from this study suggest that hesperidin solubility can be markedly 
improved by complexation with HP-β-CD and that hesperidin exhibits sufficient chemical and 
enzymatic stability in aqueous solutions and biological matrices, respectively. Additionally, 
ocular tissue permeation characteristics of hesperidin are not limited by efflux mechanisms. 
Thus, topical delivery of hesperidin in the form of ophthalmic solutions/suspensions appears 
feasible. A pH range of 6.5 - 8.5 is considered to be optimal for ophthalmic formulations. 
Considering the favorable permeability, solubility and stability profiles, it would be reasonable to 
formulate hesperidin based ophthalmic solutions at pH 7.4. Further investigation into penetration 
of hesperidin into the back-of-the eye ocular tissues, following topical and systemic 
administration is warranted. 
 
 
 
Courtesy: Reprinted with kind permission from Springer New York LLC.  Majumdar S, 
Srirangam R. Solubility, stability, physicochemical characteristics and in vitro ocular tissue 
permeability of hesperidin: a natural bioflavonoid. Pharm Res. 2009; 26(5):1217-25. 
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CHAPTER 4 : SOLUBILITY, STABILITY, PHYSICOCHEMICAL 
CHARACTERISTICS AND IN VITRO OCULAR TISSUE PERMEABILITY 
OF HESPERETIN 
 
ABSTRACT 
The purpose of this investigation was to determine solubility, stability, and in vitro 
permeability characteristics of hesperetin across excised rabbit corneas. Aqueous and pH 
dependent solubility was determined using standard shake flask method. Solution stability was 
evaluated as a function of pH (1.2 - 9) and temperature (25 and 40°C). Permeability of hesperetin 
was determined across the isolated rabbit cornea utilizing a side-bi-side diffusion apparatus, in 
the apical to basolateral (A-B) and basolateral to apical (B-A) directions. Hesperetin displayed 
asymmetrical transcorneal transport with a 2.3-fold higher apparent permeability in the B-A 
direction compared to the A-B direction. The transport process was observed to be pH 
dependent. Surprisingly, however, the involvement of efflux transporters or proton-coupled 
carrier-systems was not evident in this asymmetric transcorneal diffusion process. The passive 
and pH dependent corneal transport of hesperetin could probably be attributable to corneal 
ultrastructure, physicochemical characteristics of hesperetin and the role of transport buffer 
components. 
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INTRODUCTION  
In order for a drug to be effective in the treatment of ocular diseases, therapeutic 
concentrations need to be achieved and maintained at the target site. Ocular drug levels may be 
achieved through topical, periocular, intravitreal, systemic or oral administration. Following 
administration, the therapeutic moiety has to cross the relevant ocular physiological barriers like 
the cornea, sclera, choroid and retinal pigmented epithelium (RPE), depending on the route of 
drug application and the target site. To diffuse across these ocular tissues, the drug molecule 
should demonstrate adequate permeability characteristics, which in turn depends on the 
physicochemical properties of the compound.  
Hesperetin has been reported to be a substrate of efflux proteins as well as proton 
dependent influx transporters, although there are conflicting reports (25, 114-116). The corneal 
tissue is reported to express several efflux transporters such as P-glycoprotein (P-gp), multi-drug 
resistant proteins (MRP) and breast cancer resistant proteins (BCRP) (108, 117). Additionally, 
peptide transporters, amino acid transporters, monocarboxylic acid transporters (MCTs) are 
amongst the identified influx transporters present on the corneal epithelium (108). Incidentally 
one report suggested the involvement of an MCT type transporter in the transcellular transport of 
hesperetin (25).  
The current project was undertaken to evaluate the in vitro permeability characteristics of 
hesperetin across the isolated rabbit cornea. Additionally, solubility, stability, and 
physicochemical properties of hesperetin were also determined.  
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MATERIALS AND METHODS 
Materials 
Hesperetin, verapamil, MK-571, erythromycin and 2-hydroxypropyl beta cyclodextrin 
(HP-β-CD) (1300 MW 0.6 substitution) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA).  Sodium azide, ouabain, probenecid, 2, 4, dinitrophenol (2, 4 DNP) were obtained from 
Fisher scientific (Fairlawn, NJ, USA). All other solvents and chemicals were also purchased 
from Fisher scientific (Fairlawn, NJ, USA) and used as such. 
Ocular Tissues 
Corneas were isolated from euthanized adult male, albino, New Zealand rabbits weighing 
between 2 - 2.5 Kg (Myrtle’s Rabbitry, Thompson Station, TN, USA). All experiments using 
rabbits conformed to the Association of Research in Vision and Ophthalmology (ARVO) 
statement on the use of Animals for use in Ophthalmic and Vision Research and followed the 
University of Mississippi Institutional Animal Care and Use Committee approved protocol (07-
024).  
Solubility Studies 
Aqueous solubility of hesperetin was determined using the standard shake flask method 
wherein an excess quantity of drug was added to 5 mL of the solvent in tightly capped glass 
vials. Samples were constantly agitated at 75 rpm, at room temperature (25 °C), for 24 h in 
reciprocating water bath (Fisher Scientific, USA) for uniform mixing. At the end of 24 h, 
samples were centrifuged (accuSpin 17R, Fisher Scientific, USA) and the supernatant was 
aliquoted and analyzed for drug content. Solubility was determined in water and in buffers (pH 
1.3 to 9) prepared following procedures described in the United States Pharmacopoeia. 
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Additionally, effect of surfactants (Tween® 80, Cremophor® EL, D-alpha-tocopheryl 
polyethylene glycol 1000 succinate (Vitamin E-TPGS), and sodium lauryl sulphate; all at 1 % 
w/v concentration) and HP-β-CD on the solubility of hesperetin was evaluated. HP-β-CD 
concentrations used for the phase solubility studies were 1, 2.5, 5, 7.5, 10, 15 and 20 % w/v in 
water. 
Solution Stability 
Stability of hesperetin in aqueous solution was determined at various pH (1.3, 3, 5, 7.4, 
and 9) and temperature (25 and 40 °C) conditions. Buffers were prepared following USP 
procedures. Stability studies were initiated with the addition of hesperetin stock solution to 5 mL 
of the respective buffer previously equilibrated to either 25 or 40 °C. The final concentrations of 
hesperetin in these solutions were 5 µg/mL. Aliquots (200 µL) were collected at predetermined 
time points and were stored at −80 °C until further analysis. Samples were analyzed using HPLC 
technique as described under the analytical method section. 
LogP and pKa 
Predicted value of LogP and pKa were obtained using ACD/I-Lab Web Service 
(ACD/LogP 8.02) and (ACD/pKa 8.03), respectively. 
Transcorneal Permeation Experiments 
Experiments were performed following previously described procedures (118). Briefly, 
studies were carried out using a side-bi-side diffusion apparatus (PermeGear, Inc. USA). Rabbits 
were euthanized with an overdose of sodium pentobarbital injected through the marginal ear 
vein. Eyes were collected immediately and washed with Dulbecco’s Phosphate Buffered Saline 
(DPBS) and the corneas were isolated with a ring of sclera around it, to help in mounting 
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between the diffusion cells. Corneas were washed in DPBS and mounted on the side-bi-side 
diffusion apparatus (standard 9 mm cells were used) with the epithelial side facing the donor cell 
for apical to basolateral transport (A–B), and with the endothelial side facing the donor cell for 
basolateral to apical transport (B–A). Temperature of the cells was maintained at 34 °C with the 
help of a circulating water bath. In all cases, unless otherwise mentioned, 3 mL of transport 
buffer (DPBS, pH 7.4, containing 0.5 % w/v HP-β-CD) or drug solution (150 µM hesperetin in 
DPBS, pH 7.4 or 6, with 0.5 % w/v HP-β-CD) was added to the apical side of the cornea while 
3.2 mL of the drug solution or transport buffer, respectively, was added to the basal side, to 
maintain the natural hydrostatic pressure. Aliquots (200 µL) were removed at predetermined time 
points (15, 30, 45, 60, 90, 120, 150 and 180 min) from the receiver side and the volume 
withdrawn was replaced with an equal volume of transport buffer. Samples were stored at −80 
°C until further analysis. 
pH Dependent Transport 
Donor solution pH was decreased to 6 from 7.4 using dilute HCl solution. Effect of pH 
on transcorneal diffusion was evaluated in both A-B and B-A directions.  
Inhibition Experiments 
Hesperetin’s corneal permeation was determined in the presence of inhibitors of various 
transport systems. Permeation of hesperetin in the A-B direction was studied in the presence of 
100 µM verapamil, 100 µM erythromycin, 500 µM 2,4 DNP, 1 mM sodium azide, and 1 mM 
ouabain.  Transport in the B-A direction was carried out in the presence of 100 µM verapamil, 
100 µM erythromycin, 50 µM chrysin, 1 mM probenecid, 50 µM MK 571, 1 mM sodium azide, 
and 1 mM ouabain. In the studies using sodium azide and ouabain, corneas were presoaked in the 
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respective transport media (with inhibitors but no drug) for 30 min before the initiation of the 
transport studies. Transcorneal permeation of hesperetin, in A-B direction, in the presence of 2, 4 
DNP transport was studied across a pH gradient, with the donor solution pH adjusted to 6 and the 
receiver solution pH at 7.4. 
Concentration Dependent Transport 
Permeation of hesperetin in the A-B direction as a function of drug concentration (from 
25 to 500 µM), was determined. Transcorneal permeation protocols as described earlier were 
followed.  
Transcorneal Permeation in the Presence of Tween® 80 
To see the effect of components of transport medium on asymmetrical transport of 
hesperetin, transcorneal permeation was carried out in the presence of 0.25 and 0.5 % w/v 
Tween® 80 in DPBS (pH 7.4), instead of HP-β-CD, in both A-B and B-A directions. 
Transcorneal permeation protocols as described earlier were followed.  
Corneal Integrity 
In order to ascertain that the integrity of the corneas were maintained under the 
experimental conditions employed, control studies were carried out using acyclovir (ACV; 1 
mM), as a marker compound. Corneal permeability, both A-B and B-A, of ACV was determined 
in the presence of hesperetin and components of the transport medium (0.5% HP-β-CD or 
Tween® 80). In these studies samples were analyzed for both ACV and hesperetin content and 
the transcorneal permeability values for both were determined. 
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Permeation across Sclera and Retinal Pigmented Epithelium (RPE) 
Transscleral permeation studies were carried out according to previously described 
procedures12. Briefly, diffusion studies were carried out using the 5 mm diameter Valia-Chein 
side-bi-side diffusion cells from PermeGear, Inc. Rabbit eyes were collected as described in the 
earlier section. Subsequently, sclera alone, or sclera with RPE/choroid was carefully isolated and 
the tissues were mounted in a manner such that outer surface of the sclera, known as the 
episclera, faced the donor side and the inner side of sclera, or the RPE side, faced the receiver 
chamber for the transport studies in the sclera to choroid/RPE direction (S to R direction). Donor 
solution was added to the RPE/choroid side for transport in the RPE/choroid to scleral direction 
(R to S direction). Temperature of the cells was maintained at 37°C with the help of a circulating 
water bath. Donor solution was composed of 150 µM hesperetin in DPBS pH 7.4 with 0.5% HP-
β-CD. DPBS with 0.5% HP-β-CD was used as the receiver solution. Aliquots (200 µL) were 
removed at predetermined time points (15, 30, 45, 60, 90, 120, 150 and 180 min) from the 
receiver side and replaced with an equal volume of transport buffer. Samples were stored at 
−80°C until further analysis. 
Analytical Method 
Hesperetin content in the samples was estimated using an analytical method based on 
reversed phase HPLC. An HPLC system equipped with Waters 600 pump controller, 2470 dual 
wavelength UV detector, refrigerated 717 plus auto-sampler and Agilent 3394B integrator was 
used. The detector was operated at 284 nm. Mobile phase consisted of 20 mM monobasic 
potassium phosphate (pH adjusted to 2.5 with orthophosphoric acid) and acetonitrile in a ratio of 
50:50 and the flow rate was maintained at 1 mL/min. A Waters Symmetry Shield C18 column 
was used. ACV content was determined following previously published methods (119). 
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Data Analysis 
Parameters associated with drug diffusion across the cornea like rate, flux and apparent 
permeability coefficient were calculated following previously described methods (118). Briefly, 
Steady state (SS) fluxes (µg/min/cm2) were determined from the slope of the cumulative amount 
of drug (M) transported vs. time (t) graph and expressed as per unit of surface area (A) as 
described by Equation 1. 
A
(dM/dt)
(J)Flux =
      Eq - 1 
Membrane permeability (cm/s) values were determined by normalizing the steady state 
fluxes to the donor concentration, Cd according to Equation 2. 
Permeability (Papp) = Flux/Cd    Eq-2  
Statistical analysis was carried using JMP software (Version 5.0.1). ANOVA was used to 
see the difference among different groups and a student t-test for the difference between two 
groups. A p value less than 0.05 is considered statistically significant. 
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RESULTS 
Solubility Studies 
Saturation solubility of hesperetin in water was found to be 15.72 ± 0.58 µg/mL and was 
pH dependent. Solubility increased with an increase in solution pH. Presence of surfactants also 
improved hesperetin’s aqueous solubility. Solubility of hesperetin in water, various buffers and 
surfactant solutions is presented in Table 4.1. 
 
Table 4.1: Saturation solubility of hesperetin in water, buffers (200 mM), and surfactant 
solutions (1 % w/v). Samples were kept under constant agitation for 24 h at 25 °C in a shaking 
water bath. Values are represented as mean ± SD (n=3). 
 
Solvent Saturation Solubility (µg/mL) 
Water 15.72 ± 0.58 
Buffer (pH 1.3) 8.56 ± 1.31 
Buffer (pH 3.0) 11.32 ± 0.60 
Buffer (pH 5.0) 9.33 ± 1. 31 
Buffer (pH 7.4) 19.58 ± 3.32 
Buffer (pH 9.0) 500.26 ± 69.75 
Tween® 80 solution 269.21 ± 10.92 
Cremophor® EL solution 255.21 ± 64.68 
Vitamin E-TPGS solution 340.49 ± 19.65 
SLS solution 300.82 ± 16.80 
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Hesperetin’s solubility was dramatically increased in the presence of HP-β-CD.  Phase 
solubility studies were conducted as a function of increasing concentrations of HP-β-CD. A plot 
of HP-β-CD concentration against the saturation solubility of hesperetin yielded an AL type 
phase solubility curve (Fig. 4.1). Association constant (K), complexation efficiency (CE) and 
regression coefficient (R2) were found to be 991 ± 4 M-1, 0.079 ± 0.005 and 0.9953 ± 0.0043, 
respectively.  
 
 
Figure 4.1: Phase solubility of hesperetin in the presence of 2-hydroxypropyl beta cyclodextrin 
(HP-β-CD). The study was carried out at a temperature of 25 °C for 24 h. Values are represented 
as mean ± SD (n=3). 
 
Stability in Aqueous Solutions 
Aqueous solution stability was tested as a function of pH and temperature. Hesperetin 
was observed to be stable in pH 1.2, 3 and 5 buffers for 3 months (last time point tested). 
However, apparent first order degradation was observed in pH 7.4 and 9 solutions and the 
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degradation rates were temperature dependent. The apparent first order degradation rate 
constants (K) and estimated half-lives are presented in table 4.2.  
Table 4.2: Solution stability of hesperetin as a function of pH and temperature. Values are 
represented as mean ± SD (n=3). 
 
pH Temperature (°C) K (day-1) t1/2 (days) 
7.4 25 0.010 ± 0.0003 72 ± 2 
7.4 40 0.041 ± 0.0007 17 ± 0.3 
9 25 0.021 ± 0.0007 34 ± 1 
9 40 0.121 ± 0.012 6 ± 0.6 
 
 
Log P and pKa 
Using ACD/LogP and ACD/pKa softwares, hesperetin’s logP was estimated to be 2.90 ± 
0.39 and pKa values were calculated to be 9.65, 8.5, and 7.55 for the hydroxyl groups positioned 
at 3', 5, and 7, respectively. 
Transcorneal Permeability 
Transport in the Apical to Basolateral (A-B) and the Basolateral to Apical (B-A) Directions: 
Hesperetin’s apparent permeability coefficients across the isolated rabbit cornea are 
presented in table 4.3.  In this case, both donor and receiver chamber pH was maintained at 7.4. 
Apparent permeability of hesperetin in the B-A direction was significantly higher, by about 2.3-
fold, than that in the A-B direction. 
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Table 4.3: Apparent permeability coefficients of hesperetin across the isolated rabbit cornea. 
Transport was carried out in a side-bi-side diffusion apparatus at a temperature of 34 °C. Donor 
solution contained 150 µM hesperetin. Values are represented as mean ± SD (n=4). 
 
Direction and pH of Diffusion Media 
Apparent Permeability 
Coefficient (cm/s) 
Apical (pH 7.4) to basolateral (pH 7.4) direction 4.31 ± 0.73 X 10-6 
Basolateral (pH 7.4) to apical (pH 7.4) direction 10.12 ± 1.92 X 10-6 
Apical (pH 6.0) to basolateral (pH 7.4) direction 16.65 ± 3.72 X 10-6 
Basolateral (pH 6.0) to apical (pH 7.4) direction 15.89 ± 3.38 X 10-6 
 
 
Inhibition Studies 
Asymmetric transport of hesperetin across the cornea, in the absence of a proton gradient, 
could be due to the involvement of influx / efflux transporters. In order to establish / identify the 
involvement of a carrier system, hesperetin transport was carried out in the presence of 
inhibitors/substrates of various nutrient transporters. The pH of the receiver and donor chamber 
solutions were maintained at 7.4. Verapamil (a known P-gp substrate) or erythromycin (a known 
P-gp/MRP inhibitor), did not produce a significant difference in the permeability of hesperetin, 
in either direction. The metabolic inhibitors ouabain (a Na+/K+ ATPase inhibitors) and sodium 
azide (an uncoupler of oxidative phosphorylation) also did not demonstrate any effect on the 
transcorneal permeation of hesperetin. Additionally, B-A transport of hesperetin was studied in 
the presence of inhibitors of other nutrient transport systems. MK571 (a specific MRP inhibitor), 
chrysin (a specific BCRP inhibitor) or probenecid (a specific OCT inhibitor) did not effect 
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transcorneal hesperetin permeability. Furthermore, diffusion in the B-A direction was studied in 
a sodium free media, to check for the involvement of a sodium dependent transporter. In this 
case also a significant change in apparent permeability was not observed (Fig. 4.2 and 4.3).  
 
 
Figure 4.2: Transcorneal permeability of hesperetin (HT) (150 µM) in the apical to basolateral 
(A-B) direction alone and in the presence of various drug transporter inhibitors. Values are 
represented as mean ± SD (n=4). 
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Figure 4.3: Transcorneal permeability of hesperetin (HT) (150 µM) in the basolateral to apical 
(B - A) direction alone and in the presence of various drug transporter inhibitors and in a sodium 
free media. Values are represented as mean ± SD (n=4). 
 
pH Dependent Transport 
Donor solution pH was decreased from 7.4 to 6, and transport was evaluated in both A-B 
and B-A directions. In the presence of a proton gradient, hesperetin exhibited a higher apparent 
permeability in both A-B (a 4-fold increase) and B-A (a 1.5-fold increase) directions, compared 
to its apparent permeability in the absence of a proton gradient (donor and receiver solution pH: 
7.4) in the A-B and B-A directions. Since, hesperetin demonstrated greater permeability in the 
presence of a proton gradient, transport studies were repeated in the presence of a protonophore, 
2, 4 DNP. A significant change in transcorneal hesperetin transport was however, not evident. 
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Concentration Dependent Transport: 
Hesperetin’s transport in the A-B direction as a function of donor concentration was 
studied to further investigate the asymmetrical transport characteristics. Both donor and receiver 
solution pH was maintained at pH 7.4. A linear increase in the flux with an increasing 
concentration of hesperetin was observed in the concentration range tested (Fig. 4.4). 
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Figure 4.4: Concentration dependent transcorneal flux of hesperetin in the apical to basolateral 
direction. Values are represented as mean ± SD (n=4). 
 
Transcorneal Permeation in the Presence of Tween® 80: 
Hesperetin’s apparent permeability coefficients across the cornea in the presence of 0.25 
% w/v Tween® 80 were found to be 5.37 ± 1.3 X 10-6 and 7.85 ± 1.6 X 10-6 cm/s in the A-B and 
B-A directions, respectively.  In the presence of 0.5 % w/v Tween® 80 apparent permeability 
coefficients were found to be 2.80 ± 0.6 X 10-6 cm/s in the A-B direction and 3.60 ± 0.8 X 10-6 
cm/s in the B-A direction. Thus, in the presence of 0.25 % and 0.5 % w/v Tween® 80, a 1.5-fold 
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and a 1.3-fold difference, respectively, exists between the A-B and B-A apparent permeability 
values. 
Corneal Integrity 
Corneal permeability of ACV in plain DPBS was observed to be 2.86 ± 0.86 x 10-6 and 
3.28 ± 0.91 x 10-6 cm/s in the A-B and B-A directions, respectively. The difference in the 
permeability values was not statistically different. In the presence of hesperetin and HPβCD or 
hesperetin and Tween® 80, a significant difference between the A-B and B-A permeability 
values of ACV was also not evident, indicating that the corneal integrity was not compromised 
under the experimental conditions employed. While ACV did not show any difference in the A-
B and B-A corneal permeability values, a significant difference (2.3-fold and 1.4-fold in the 
presence of HP-β-CD and Tween 80, respectively) was observed with respect to the corneal 
permeability of hesperetin. 
Transscleral Permeability 
Transscleral permeability studies were conducted using Valia-Chein diffusion cells. A 
significant difference in hesperetin’s permeability in the S-R and R-S direction was not observed 
(Fig. 4.5). Permeability of hesperetin across the sclera alone was much higher (6-fold) compared 
to permeability across the sclera with RPE attached (sclera-choroid-RPE). 
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Figure 4.5: Transscleral permeability of hesperetin (150 µM) across rabbit sclera and sclera-
choroid-RPE. S–R and R–S denotes permeation in the sclera to RPE direction and RPE to sclera 
direction, respectively. Values are represented as mean ± SD (n=4). 
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DISCUSSION 
Hesperetin has the potential to treat multiple ocular diseases like diabetic retinopathy, 
diabetic macular edema and cataract, by virtue of its wide-ranging pharmacological activities 
(70, 81, 120, 121). However, drug delivery to the eye is a challenging task and successful 
ophthalmic formulation development requires an understanding of the physicochemical and 
permeability characteristics of a drug molecule. The current research project was undertaken to 
delineate the in vitro permeation profile of hesperetin across isolated rabbit corneal tissue.  
Hesperetin demonstrated very poor aqueous solubility and exhibited a pH dependent 
solubility profile. While a significant difference in solubility was not observed in the acidic pH 
range (1.3, 3, and 5), under alkaline conditions solubility increased with an increase in solution 
pH (Table 4.1). Hesperetin possesses three phenolic hydroxyl groups (Fig. 2.2), and thus 
behaves like a weak acid. However, all the predicted pKa values are above 7.5, suggesting 
hesperetin will dissociate under alkaline pH conditions.  Consistent with this, higher aqueous 
solubility was observed in the basic pH range. Presence of HP-β-CD significantly increased 
aqueous solubility of hesperetin and this is in agreement with earlier reports (105). A linear 
increase in solubility with increasing concentrations of HP-β-CD (Fig. 4.1) indicates that HP-β-
CD is probably forming a 1:1 molar complex with hesperetin. From the phase solubility studies, 
the complexation efficiency for hesperetin and  HP-β-CD was found to be relatively high 
compared to hesperidin (118), its parent compound. This could be due to the much higher 
lipophilicity of hesperetin (logP 2.9) compared to hesperidin (logP 1.78). Hesperetin was found 
to be stable in the acidic buffers (pH 1.2 - 5). However, hesperetin’s concentration was found to 
decrease with time with an increase in solution pH and temperature (pH 7.4 – 9) (Table 4.2). 
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Transcorneal diffusion of hesperetin was studied using an in vitro side-bi-side diffusion 
apparatus. The studies were carried out using DPBS (pH 7.4) containing 0.5 % w/v HP-β-CD as 
the transport medium. Hesperetin exhibited asymmetric permeability across the isolated rabbit 
cornea, with the apparent permeability in the B-A direction being 2.3-fold greater than that in the 
A-B direction. Higher B-A apparent permeability could indicate the involvement of the efflux 
transporters (e.g. MRP, P-gp and BCRP) expressed on the corneal epithelium (108, 117). Earlier 
studies, however, present confounding evidence with respect to the interaction of hesperetin with 
efflux transporters (25, 114, 116, 122). Kobayashi et al., demonstrated that a proton-coupled and 
energy dependent transporter was responsible for this higher A-B flux across the Caco-2 cells 
(25). Other researchers, however, reported symmetrical transport of hesperetin across Caco-2 
cells (116) and that hesperetin’s A-B transport was unaltered in the presence of specific 
inhibitors of different ABC transporters, signifying that hesperetin moves through the Caco-2 
cell monolayer by passive diffusion (114, 122).  
In the current study, the apparent transcorneal permeability profile of hesperetin 
suggested possible involvement of efflux transporters in the permeation process. However, a 
significant increase in the A-B transport of hesperetin in the presence of verapamil and 
erythromycin (P-gp and MRP inhibitors) or sodium azide and ouabain (metabolic inhibitors) was 
not evident (Fig. 4.2). To further investigate the role of influx drug transporters in hesperetin’s 
asymmetric transcorneal transport, B-A transport was studied in the presence of verapamil, 
erythromycin, MK-571 (P-gp/MRP inhibitors), probenecid (OATP inhibitor), chrysin (BCRP 
inhibitor), sodium azide, and ouabain. Hesperetin’s B-A transport remained unaltered in all cases 
(Fig. 4.3). These results suggest that the B-A diffusion of hesperetin is not facilitated by any of 
the transporters tested, and that the transport process is energy and sodium independent since 
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both sodium azide and ouabain produced an insignificant effect on transcorneal drug transport. 
Moreover, transporter involvement typically yields a curvilinear or saturable concentration 
dependent flux. However, in the present study, transcorneal hesperetin flux, in the A-B direction, 
increased linearly with increasing concentrations of hesperetin (Fig. 4.4), within the 
concentration range tested. The above results, taken together, strongly suggest that corneal 
influx/efflux transporters do not interact with hesperetin and are not responsible for the observed 
asymmetric transcorneal transport of hesperetin. 
It is evident from the pH dependent solubility studies, and the pKa value (9.65, 8.5, and 
7.55) of the drug molecule, that hesperetin undergoes ionization and would thus exhibit pH 
dependent permeability rates. To evaluate the effect of ionization on transcorneal hesperetin 
permeability, the studies were repeated with the donor solution pH adjusted to 6. The receiver 
solution pH was maintained at 7.4. This resulted in a significant increase in hesperetin’s apparent 
permeability in both A-B and B-A directions (Table 4.3), although the increase in the A-B 
direction was significantly greater than the increase in the B-A direction. At a lower pH value 
(pH 6), greater than 95% of the drug exists in the unionized state (pKa 7.55), which would 
explain the higher permeability of hesperetin. The higher A-B flux of the drug could also be 
because of a proton-coupled transporter. However, in the presence of a protonophore, 2, 4 DNP, 
a significant change in the apparent A-B permeability was not evident, eliminating the 
involvement of a proton-coupled carrier system.  
To evaluate the effect of the transport medium (especially HP-β-CD), apparent 
transcorneal permeability of hesperetin was evaluated using DPBS (pH 7.4) containing 0.25% or 
0.5% w/v Tween® 80 instead of HP-β-CD. Transport in the B-A direction was 1.5 and 1.3-fold 
higher compared to the A-B direction, in the presence of 0.25 and 0.5 % w/v Tween® 80, 
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respectively. This study further supports the observation that transport of hesperetin across the 
rabbit cornea is asymmetrical, especially at lower concentrations of the surfactant. Transcorneal 
permeability coefficient of hesperetin in the presence of 0.25 % w/v Tween® 80 was 2-fold 
greater than that in the presence of 0.5 % w/v Tween® 80. This is probably because of increased 
micellar entrapment of the drug (same drug concentration but increased surfactant levels). This is 
consistent with other studies reporting a decrease in apparent permeability with increasing 
surfactant concentration (123).  
Considering, hesperetin exhibits asymmetrical transport across the rabbit cornea in the 
absence of a proton gradient and symmetrical transport in the presence of a proton gradient, and 
that the corneal influx or efflux transporters are not involved in the process, the following 
hypothesis could probably explain the observed results. Figures 4.6 and 4.7 illustrate the theory 
schematically. 
The three physical barriers associated with transcorneal diffusion are the epithelium, the 
stroma and the endothelium. Drug transport across these different corneal layers can be 
represented by Fick’s first law of diffusion. 
According to Fick’s first law of diffusion 
dM
dt
= 
DSKp (Cd - Cr)
h
    Eq-4 
Where, dM/dt is the mass transfer rate, D is the diffusion coefficient, S is the surface 
area, Kp is the apparent partition coefficient, Cd is the concentration of hesperetin in the donor 
compartment, Cr is the concentration of hesperetin in the receiving compartment, (Cd - Cr) is the 
concentration gradient, and h is the membrane or barrier thickness. 
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Figure 4.6: Schematic representation of the transport of hesperetin across rabbit corneal layers in 
the apical to basolateral (A-B) direction. Thicker arrows denote the higher flux. 
 
 
 
Figure 4.7: Schematic representation of the transport of hesperetin across rabbit corneal layers in 
the basolateral to apical (B-A) direction. Thicker arrows denote the higher flux. 
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Consider  
‘DSKp/h’ as ‘K’ and  
(Cd-Cr) equals Cd (as Cd>>Cr). 
When hesperetin is permeating in the A-B direction, the net mass transfer rate can be described 
by equation 5 
dM
dt 
 A  B   K1
CUIDn   K2
CIDn   K3
CUIEp   K4
CUISt   K5
CISt   K6
CUIEnd        Eq-5 
where K1, K2, ……and K6 are the rate constants associated with the diffusion of the drug; 
[CUI] represents concentration of unionized hesperetin;  [CI] represents concentration of ionized 
hesperetin. The subscripts Dn, Ep, St and End represent concentration of the drug in donor 
chamber, corneal epithelial cells, corneal stroma and corneal endothelial cells, respectively. 
Hesperetin is known to cross biological barriers by both paracellular as well as 
transcellular pathways (114). In the A-B direction, the corneal epithelium, comprised of multiple 
layers of epithelial cells packed tightly together, is the first barrier encountered. When the donor 
solution is maintained at pH 7.4, hesperetin (pKa 7.55) exists in both the unionized (UI) and 
ionized (I) states and only the unionized fraction would diffuse transcellularly into the epithelial 
cells (represented by K1 [CUI]Dn of equation 5). Paracellular diffusion of the ionized form 
(represented by K2 [CI]Dn of equation 5) would be negligible due to the presence of the corneal 
epithelial tight junctions. A fraction of the unionized hesperetin diffusing into the corneal 
epithelial cells, then partitions out into the stroma, which is composed of about 90 % water 
(represented by K3 [CUI]Ep of equation 5). In view of the fact that the logP of hesperetin is 2.9, it 
is reasonable to conclude that the diffusivity (D) of the drug across the epithelial cell membrane 
into the stroma will be very low and thus only a very small fraction of the unionized hesperetin 
would partition into the stroma from the epithelial layer (i.e. K3 [CUI]Ep will be very low). 
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Equilibrium between the ionized and unionized fractions would be established in the stroma (pH 
7.2 - 7.4). From the stroma the unionized fraction of hesperetin would move into the endothelial 
cell membrane at a rate represented by K4 [CUI]St of equation 5. Ionized hesperetin, a small 
molecule, can also diffuse from the stroma across the intercellular junctions of the corneal 
endothelial cell layer (represented by K5 [CI]St of equation 5), which are leaky in nature (110), 
into the receiver solution. The final component of the overall diffusion process would be the 
movement of drug into the receiver solution from the endothelial cells (represented by K6 
[CUI]End of equation 5) which would be facilitated by, HP-β-CD or Tween® 80, solubilizing 
components of the receiver solution.  
Thus, with respect to transcorneal A-B transport, the epithelial tight junctions, blocking 
the diffusion of ionized hesperetin (K2 [CI]Dn), and poor partitioning of the unionized hesperetin 
from the corneal epithelial layer into the stroma (K3 [CUI]Ep) act as the rate limiting steps in the 
transcorneal diffusion process. The above is schematically represented in Figure 4.5. 
On the other hand when hesperetin is diffusing in the B-A direction, the net mass transfer 
rate can be described by equation 6 
dM
dt 
 B-A= K7[CUI]Dn+ K8[CI]Dn+ K9[CUI]End+ K10[CUI]St+ K11[CI]St+ K12[CUI]Ep      Eq-6 
where, K7, K8, ……and K12 are the rate constants associated with diffusion of the drug;. 
This has been schematically described in Fig. 4.6. 
In the B-A direction the endothelial cells do not present a formidable barrier to the 
diffusion of the unionized (represented by K7 [CUI]Dn of equation 6) or ionized (represented by 
K8[CI]Dn of equation 6) hesperetin fractions into the corneal stroma because of a decreased 
transcellular diffusion length (single layered endothelial cells compared to the multilayered 
corneal epithelium) and the lack of endothelial cell tight junctions, respectively. This is 
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consistent with several studies that demonstrate transport across the corneal endothelial cells is 
much higher than that across the epithelial cells for several drugs (110). In the stroma, since the 
pH is 7.4, equilibrium between the ionized and unionized hesperetin fractions is established. 
Considering the less restricted access of the ionized form to the stroma in the B-A direction, 
stromal hesperetin concentrations will be significantly higher than that achieved in the A-B 
direction.  
(([CUI] + [CI])St)B-A >> (([CUI] + [CI])St)A-B   Eq-7 
The unionized hesperetin then readily partitions into the corneal epithelial cells, from the 
stroma, because of its lipophilic nature (represented by K10 [CUI]St of equation 6). In contrast to 
the A-B direction, wherein the drug does not easily partition out from the epithelial layers into 
the stroma, in this case, because of higher logP, diffusivity will be high and overall  
K10 [CUI]St >> K3 [CUI]Ep     Eq-8 
From the epithelial cells, drug partitioning into the receiver chamber will be facilitated by 
HP-β-CD or Tween® 80, present in the receiver solution (represented by K12 [CUI]Ep of equation 
6). Moreover, the paracellular transport of hesperetin across the corneal epithelium in the B-A 
direction (represented by K11 [CI]St of equation 6) could also be significantly higher than that in 
the A-B direction because of the structural organization of the tight-junctions (39). Thus, 
K11 [CI]St >> K2 [CI]Dn or  
K11 [CI]Dn >> K2 [CI]Dn  (refer to eq-7) 
This is also consistent with the report from Pezron et al., wherein the authors observed a 
higher flux of zinc insulin in the B-A direction compared to A-B direction across Calu-3 cell 
monolayers. It was found that efflux by a transporter (P-gp), enzymatic degradation or the 
abundant insulin transporters on the basolateral side were not responsible for this asymmetric 
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transport of insulin. The authors hypothesized that at the apical surface diffusion of insulin 
monomers is restricted by the presence of tight junction complexes, however, on the basolateral 
side insulin oligomers can diffuse into the intercellular spaces freely and dissociate and diffuse 
readily as monomers to the apical surface (124).  
Considering better transcellular and paracellular diffusion rates in the B-A direction, the 
overall permeability in the B-A direction is greater. Differently stated, when hesperetin is 
diffusing in the B-A direction, the stroma is exposed to higher drug concentrations, thus 
narrowing down the diffusion path length by acting as a donor. On the other hand, in the A-B 
direction, the stroma holds relatively much lower fractions of hesperetin because of the larger 
barrier role of the epithelial cell layer in this case. Thus, low drug flux is observed in this 
direction. This hypothesis explaining the asymmetrical transcorneal diffusion of hesperetin is 
consistent with the reports of Schultz, which documents that passive asymmetric transport 
through the biological membranes is possible, and that this could be attributed to the structural 
heterogeneity of the biological membrane (125). 
When the donor solution pH was decreased to pH 6, however, transcellular diffusion of 
hesperetin in the A-B direction increased dramatically (4.5-fold increase) due to a significantly 
higher concentration gradient of the unionized species. As a result more drug partitioned into the 
corneal epithelium and thus into the stroma and thus higher net diffusion in the A-B direction 
was observed. Moreover, unionized (uncharged) hesperetin molecules would demonstrate better 
paracellular diffusion characteristics than the negatively charged species (126). Thus, in the A-B 
direction, with the donor solution at pH 6, both transcellular as well as paracellular diffusion 
rates would increase. 
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On the other hand, when the donor solution was at pH 6, the B-A transport increased less 
markedly (1.5-fold) since trans-endothelial diffusion of hesperetin was anyway higher to start 
with. The slight increase observed would be because of increased transcellular diffusion of the 
unionized form and also improved paracellular diffusion of the unionized hesperetin molecule 
(both across endothelial and epithelial cell junctions). On the whole, transcellular diffusion rates 
would overshadow the paracellular diffusion component of hesperetin in the unionized state. 
Consequently A-B and B-A transport becomes equal when the donor solution pH is maintained 
at pH 6, i.e. the molecule exists in the unionized state. 
It also appears that the composition of the transport medium could significantly affect the 
transcorneal transport symmetry. The difference between the A-B and B-A flux was significantly 
greater when HP-β-CD was used as the solubilizer. Considering the geometrical configuration, 
number of hydrogen bonding sites and the molecular weight of HP-β-CD, there is very little 
chance that HP-β-CD could penetrate into the stroma from the basolateral side. On the other 
hand the ability of Tween® 80 to diffuse into the stroma through the endothelial cells may be 
much greater because of its comparatively linear structure. Presence of a solubilizer in the stroma 
would significantly enhance K3[CUI]Ep, and thus decrease the difference between the A-B and B-
A diffusion rates. At 0.25% w/v the concentration of Tween® 80 generated in the stroma would 
be significantly lower than that obtained with 0.5% Tween® 80. Consequently, with 0.25% 
Tween® 80 a greater directional diffusion was observed compared to that with 0.5% Tween® 80. 
There could be an argument that at higher surfactant concentrations the biological membranes 
would be damaged. To check for this ACV, a molecule that traverses the corneal membrane 
primarily by diffusion across the paracellular pathway, was included as an internal marker. In the 
same experimental set-up, while ACV demonstrated symmetrical transport across the cornea, 
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hesperetin demonstrated asymmetrical transport. This demonstrates that a change in corneal 
integrity was not responsible for the directionality in the observed transcorneal permeation of 
hesperetin. Moreover, a decrease in the overall transcorneal hesperetin flux, at 0.5% Tween® 80, 
further indicates lack of surfactant induced membrane damage. 
In recent years the transscleral route has gained a lot of attention as a means of treating 
posterior segment diseases(127). In vitro transscleral permeation studies of hesperetin revealed 
that it is capable of permeating across these ocular barriers. It was observed that the drug 
permeates across the sclera easily. However the choroid-RPE acts as a significant barrier to the 
movement of the drug. Significant differences in hesperetin’s permeability as a function of 
direction, i.e. S-R and R-S were not observed, signifying the lack of involvement of any carrier 
mediated system (Fig. 4.5). Earlier studies (128, 129) demonstrate that the sclera is permeable to 
higher molecule weight compounds also. Therefore, HP-β-CD, a component of the diffusion 
media with a molecular weight of 1300 Daltons, is capable of diffusing across the sclera, into the 
sclera/choroidal stroma.  Thus, with respect to transscleral diffusion, since HP-β-CD can cross 
the sclera and reach the Bruch’s-choroid membrane, the diffusion path length is the same in both 
directions and comprises of the RPE and Bruch’s membrane. As a result, a difference in 
permeability in the S-R and R-S direction is not evident  Additionally, it is interesting to note 
that hesperetin’s transscleral permeability is higher than that of its parent compound hesperidin, 
which may be due to higher lipophilicity of hesperetin compared to hesperidin(118). It has been 
reported that RPE favors the diffusion of lipophilic molecules(130). 
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CONCLUSION 
In conclusion, hesperetin is capable of permeating across the corneal tissue but exhibits 
asymmetric transport with the permeability in the A-B direction being significantly lower than 
that in the B-A direction. Unique structural features of the cornea and the transport medium 
components and solution pH, rather than the involvement of influx/efflux transporters, are 
probable reason behind the higher corneal permeability of the drug in the B-A direction.  
 
 
 
 
Courtesy: Reprinted with kind permission from Elsevier BV.  Srirangam R, Majumdar S. Passive 
asymmetric transport of hesperetin across isolated rabbit cornea. Int J Pharm. 2010; 394 (1-2): 
60-7. 
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CHAPTER 5 : INTRAVITREAL KINETICS OF HESPERIDIN, 
HESPERETIN AND HESPERIDIN G: EFFECT OF DOSE AND 
PHYSICOCHEMICAL PROPERTIES 
 
ABSTRACT 
The objective of this study was to delineate the vitreal pharmacokinetics of hesperidin 
and hesperetin and the hydrophilic derivative hesperidin G (glucosyl hesperidin), following 
intravitreal administration in anaesthetized rabbits. Concentration changes in the vitreous humor 
were monitored using microdialysis sampling procedure. All three molecules were administered 
intravitreally at three dose levels (50 µL injection volume containing 1.5, 4.5 and 15 µg of the 
drug, resulting in a final vitreal concentration of 1, 3 and 10 µg/mL). Vitreal microdialysis 
samples were collected every 20 minutes over a period of 10 h. All three molecules exhibited 
linear pharmacokinetics, within the dose range tested, since AUC and Cmax increased linearly 
with increasing dose and a significant difference in the elimination parameters, like clearance or 
half-life, was not observed. The vitreal elimination half-life of these three compounds was 
observed to correlate with the molecular weight and lipophilicity of the molecules. The findings 
from this study provide practical information that will be useful in the future design of ocular 
drug delivery strategies for the bioflavonoids. 
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INTRODUCTION 
Diabetic retinopathy and diabetic macular edema are the leading causes of acquired 
blindness, especially in Western countries (55). Hesperidin, a flavanone glycoside and its 
aglycone, hesperetin have beneficial effects in the prevention or treatment of diseases of the 
posterior segment of the eye, like diabetic retinopathy, diabetic macular edema and other ocular 
disorders, because of their favorable pharmacological properties. These molecules can act as 
potential antioxidants, can increase the ocular blood flow and minimize ischemic injury to the 
retina, can decrease vascular permeability, and act as a neuroprotectant, anti-inflammatory agent 
and anticancer agent (118, 131, 132). Hesperidin G (glucosyl hesperidin) is a water soluble 
derivative of hesperidin (Figure 5.1). In hesperidin G, a glucose molecule is attached to the 
rutinose moiety of hesperidin. This improved hesperidin’s solubility several folds (133). 
Hesperidin G is also reported to have some beneficial effects (134-136). It suppressed the 
oxidative stress in the vasculature and thereby ameliorated endothelial dysfunction and 
hypertension in spontaneously hypertensive rats. However, the observed pharmacological effects 
could be because of conversion of hesperidin G into hesperidin and hesperetin by the intestinal 
or hepatic metabolic enzymes (137). 
Ameer et al., (19) reported that hesperidin’s oral bioavailability is very low (<25%). Over 
and above all the barriers to systemic bioavailability, in order to exert a therapeutic effect in 
diabetic retinopathy, these compounds must penetrate into the neural retina from the systemic 
circulation. For this, they need to permeate across the blood-retinal barrier (BRB), formed by the 
retinal pigmented epithelium (RPE) and the endothelial cells of the retinal blood vessels. The 
diffusion limiting capabilities of the BRB has been well established for both hydrophilic (limited 
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by tight junctions) as well as lipophilic (through efflux mechanism) compounds. Thus, following 
oral administration very little, if any, amounts can reach the neural retina.  
 
 
 
Figure 5.1: Chemical structure of hesperidin G (glucosyl hesperidin) 
 
Intravitreal therapy has brought about a paradigm shift in the management of posterior 
segment ocular diseases. Currently, it is approved by the US FDA to target submacular choroidal 
neovascularization in patients with AMD (36, 138). Considering back-of-the eye drug delivery, 
the major advantage of IVI is that it generates higher concentrations of the therapeutic agent in 
the vitreous with minimal or negligible systemic exposure. These injections have been used to 
deliver many types of medications into the vitreous cavity, for example anti-infective (antibiotic, 
antifungal, and antiviral), anti-inflammatory (nonsteroidal anti-inflammatory, steroids, and 
immunomodulators), anticancer and anti-VEGF agents. However, IVIs may introduce further 
complications, such as the progression of endophthalmitis and cataract due to repeated injections. 
Additionally, repeated injections may cause extreme patient discomfort and may lead to 
complications such as vitreal hemorrhage, infection, and lens or retinal injury (36, 138). In spite 
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of the above, IVIs still represent the most effective route of delivery for the back-of-the eye 
diseases. 
The duration of effect of an intravitreally administered drug depends on the retention of 
the injected drug at the site of administration. Disposition of the intravitreally administered drug 
from the vitreous humor mainly depends on the physicochemical properties of the molecule and 
metabolism by ocular metabolizing enzymes. A scientific understanding of the elimination 
kinetics of the drug from posterior chamber and its relationship with physicochemical properties 
such as molecular weight, lipophilicity and solubility is essential for the development of 
intravitreal drug delivery technologies with desired pharmacokinetic properties (36, 138-140). 
The three molecules hesperidin, hesperetin, and hesperidin G, differ in their 
physicochemical properties and molecular weight. Hesperetin has the lowest molecular weight 
(C16H14O6, 302.27 g/mole) followed by hesperidin (C28H34O15, 610.57 g/mole) and hesperidin G 
(C34H44O20, 772.70 g/mole).  Hesperidin G is significantly more hydrophilic than the other two 
molecules with a log P of < -3.2 while hesperidin and hesperetin have a log P of 1.78 and 2.9, 
respectively (118, 132). Thus, the specific objective of the current project was to evaluate the 
dose dependent vitreal disposition kinetics of the selected three compounds and to evaluate the 
role of log P, solubility and molecular weight on the vitreal elimination kinetics. In this study, 
vitreal microdialysis was used to estimate the concentration of the compounds in the vitreous 
humor. It is an invasive sampling technique, which involves surgical implantation of the probes 
into the organ/tissue of choice. It has become an important tool for dynamic in vivo sampling and 
in recent times has been effectively used in characterizing intraocular disposition of drugs in both 
the anterior and the posterior chambers of the eye (42-44, 141). 
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MATERIALS AND METHODS 
Animals  
New Zealand male white rabbits were procured from Myrtle’s Rabbitry (Thompson 
Station, TN). Experiments conformed to the tenets of the Association for Research in Vision and 
Ophthalmology (ARVO) statement on the Use of Animals in Ophthalmic and Vision Research 
and followed the University of Mississippi Institutional Animal Care and Use Committee 
(IACUC) approved protocol. Each experiment was conducted at least in quadruplicates. 
Materials 
Microdialysis probes (CMA/20; 20,000 Da molecular mass weight and 10 mm shaft) 
were obtained from CMA/Microdialysis Inc. (North Chelmsford, MA). Hesperidin and 
hesperetin were purchased form Sigma-Aldrich (St. Louis, MO). Hesperidin G was obtained as a 
gift sample from Hayashibara International Inc. (Broomfield, CO). Ketamine hydrochloride and 
xylazine were procured from Fort Dodge Animal Health (Fort Dodge, IA) and Lloyd 
Laboratories (Shenandoah, IA), respectively. Pentobarbital was obtained from Virbac AH, Inc. 
(Fort Worth, TX). All other chemicals and solvents (HPLC grade) used were purchased from 
Thermo Fisher Scientific (Waltham, MA) and used as such. 
In vitro Probe Recovery 
Microdialysis probe recovery was determined following a previously published 
report(44). Briefly, recovery values were obtained by placing the probe in an isotonic phosphate-
buffered saline (IPBS) solution (pH 7.4) at 37°C, containing a known concentration (1, 3, 10 
µg/mL) of the compound; hesperidin, hesperetin or hesperidin G. The probe was perfused with 
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sterile IPBS at different flow rates (1.8, 3 and 4 µL/min), and the dialysate was collected every 
20 min, to choose optimal conditions. Relative recovery was calculated using eq. 1: 
Recoveryin vitro = Cd/Cs   (1) 
where Cd is the concentration of the respective compound in the dialysate and Cs is the 
concentration in IPBS. The concentration of the respective compound in the vitreous humor 
samples was calculated by dividing the dialysate concentration by the in vitro recovery factor 
obtained as described above.  
The recovery factor for each probe is individually determined before and after the 
experiment and the in vivo samples obtained from each probe is uniquely coded. The mean 
recovery factor for that particular probe is then used to obtain the actual vitreous humor levels 
from the vitreous humor sample concentrations. If a significant difference in the recovery factor 
is observed between the in vitro recovery values obtained at the beginning and at the end of each 
experiment, data from that probe is not considered. Determination of the recovery factors were 
carried out for each individual compound separately. In order to validate the microdialysis probe 
recovery factor estimation in IPBS (pH 7.4), in vitro recovery was also determined in pooled 
rabbit vitreous humor (collected at the end of other experiments involving New Zealand white 
rabbits, from the same or other protocols). The same probes were used in both media. The 
concentration used for the compounds in these studies was 1 µg/mL.  
Probe Implantation 
Probe implantation was done following previously published reports (44). Briefly, rabbits 
(weighing 2–2.5 kg) were anesthetized using ketamine (35 mg/kg)/xylazine (3.5 mg/kg) 
administered intramuscularly and were maintained under anesthesia throughout the duration of 
the experiment (ketamine/xylazine administered intramuscularly every 40 min). Before probe 
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implantation, 1% tropicamide was applied topically to dilate the pupil. A 22-guage needle was 
then inserted into the posterior chamber of the eye. The point of insertion was approximately 3 
mm below the corneal-scleral limbus. The needle was withdrawn, and the vitreal probe was 
implanted immediately. The position of the probe was adjusted so that the semipermeable 
membrane was in the mid-vitreous section. The probes were continuously perfused with sterile 
IPBS (pH 7.4) at a flow rate of 3 µL/min using a CMA/100 microinjection pump 
(CMA/Microdialysis Inc.). After probe implantation, animals were allowed to stabilize for a 
period of 2 h before the administration of respective compound. Vitreal samples were collected 
every 20 min for a period of 10 h post intravitreal administration. Samples were collected in 
microcentrifuge tubes and stored at -80°C until further analysis. At the end of the study, animals 
were euthanized, under deep anesthesia, with an overdose of sodium pentobarbital administered 
through the marginal ear vein. 
Intravitreal Administration  
Hesperidin, hesperetin or hesperidin G was administered intravitreally (respective dose 
(1.5, 4.5 or 15 µg) in 50 µL of IPBS (pH 7.4)). In the case of hesperidin and hesperetin, initial 
stock was prepared using 5 % DMSO and further dilutions were made with sterile IPBS (pH 
7.4). Final concentration of DMSO in the vitreous humor ranged between 0.005 to 0.05 %. 
Analytical Methods 
Hesperidin, hesperetin and hesperetin G content in the samples was estimated using an 
analytical method based on reversed phase HPLC. An HPLC system equipped with Waters 600 
pump controller, 2470 dual wavelength UV detector, refrigerated 717 plus auto-sampler and 
Agilent 3394B integrator was used. The detector was operated at 284 nm. Mobile phase 
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consisted of 20 mM monobasic potassium phosphate (pH adjusted to 2.5 with ortho-phosphoric 
acid) and acetonitrile in a ratio of 75:25 for hesperidin and glucosyl hesperidin while a ratio of 
50:50 was used for hesperetin. The flow rate was maintained at 1 mL/min. A Phenomenex Luna, 
250 X 4.6 mm, 5µ, C18(2) column was used. Samples were injected (30 µL) on to the column as 
such. Calibration curve concentrations used were 0.02, 0.2, 0.5, 1.0, 5.0, 10.0, 15.0 µg/mL for 
hesperetin and 0.05, 0.2, 0.5, 1.0, 5.0, 10.0, 15.0 µg/mL for hesperidin and hesperidin G. The 
calibration curve had to have a correlation coefficient (r2) of 0.99 or better. Accuracy and 
precision was analyzed using four QC samples, at 0.02, 0.2, 1.0, 10.0 for hesperetin and 0.05, 
0.2, 1.0, 10.0 for hesperidin and hesperidin G. The acceptance criterion for each back-calculated 
standard concentration was 15% deviation from the nominal value except at LLOQ, which was 
set at 20%. 
Data Analysis 
Vitreal pharmacokinetic parameters were determined using WinNonlin® software 
(version 5.2; Pharsight, Mountain View, CA). Data was modeled according to one-compartment 
and two-compartment pharmacokinetic models. Akaike Information Criterion (AIC) and 
Schwarz Bayesian Criterion (SBC) were used for the selection of the most appropriate model. 
Additionally, the goodness of fit was assessed graphically by evaluation of the agreement 
between the observed and the predicted concentrations and on the correlation coefficient (R2) for 
observed vs. predicted values. Statistical analysis was carried out using JMP software (Version 
5.0.1). ANOVA was used to check for difference among different groups and Student t-test was 
used to evaluate difference between two groups. A p value less than 0.05 is considered 
statistically significant. 
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RESULTS AND DISCUSSION 
Hesperidin and its aglycone, hesperetin are potential candidates for the prevention or 
treatment of diseases of the posterior segment of the eye like diabetic retinopathy and diabetic 
macular edema (118, 131, 132). Effective concentrations of hesperidin and hesperetin for various 
pharmacological activities have been reported by several researchers. These compounds 
exhibited dose dependent activities in different in vitro (1-100 µM) (60, 72, 85, 91, 142-144) and 
in vivo studies (10-80 mg/Kg BW) (92, 120, 145-147). Hesperidin G is also reported to have 
some beneficial effects (134-136). However, the observed pharmacological effects could be 
because of conversion of hesperidin G into hesperidin and hesperetin by the metabolic enzymes 
present in the intestine or liver (137).  
Analytical method for estimating the concentration of these compounds was validated. 
Inter-day and intra-day accuracy and precision (CV %) were within 80 -120 % of nominal 
concentration at LLOQ and 85 -115 % at remaining quality control levels (Table 5.1). LLOQ for 
hesperidin and hesperidin G was found to be 0.05 µg/mL and for hesperetin 0.02 µg/mL. In this 
study, microdialysis sampling technique was used for sampling the vitreous humor. Initial 
experiments were carried out to optimize flow rate and recovery factor. It was observed that with 
an increase in perfusate flow rate, recovery factor decreased. An optimum flow rate of 3 µL/min 
was used for the in vivo studies (Table 5.2). The mean recovery values reported signify the mean 
in vitro recovery of the probe over a period of 3 consecutive sampling points (20 minutes per 
point over 3 hours) for the same probe. The in vitro microdialysis recovery factor was not 
affected by the sample concentration (1, 3, and 10 µg/mL) for the three molecules; hesperidin, 
hesperetin and hesperidin G.  
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Table 5.1: Intra-day and inter-day accuracy and precision data of quality control standards in 
IPBS (pH 7.4).  
 
Compound 
Theoretical 
Concentration 
(µg/mL) 
Measured Concentration (µg/mL) 
Intra-day variation Inter-day variation 
Mean 
(N=6) 
CV 
(%) 
Accuracy 
(%) 
Mean 
(N=4) 
CV 
(%) 
Accuracy 
(%) 
Hesperetin 
0.02 (LLOQ) 0.02 7.42 99.17 0.02 8.66 101.46 
0.20 (LQC) 0.202 2.66 100.75 0.202 2.85 100.75 
1.00 (MQC) 1.01 5.91 101.00 1.02 5.51 101.00 
10.00 (HQC) 10.01 1.43 100.10 9.97 2.17 99.68 
Hesperidin 
0.05 (LLOQ) 0.051 6.1 101.00 0.51 5.69 101.00 
0.20 (LQC) 0.203 3.53 101.58 0.203 3.13 101.46 
1.00 (MQC) 1.00 5.37 99.67 1.01 5.31 100.33 
10.00 (HQC) 10.03 1.95 100.30 10.02 1.69 100.20 
Hesperidin 
G 
0.05 (LLOQ) 0.052 9.61 103.33 0.052 8.35 103.42 
0.20 (LQC) 0.204 4.91 101.92 0.199 3.98 99.65 
1.00 (MQC) 1.02 6.36 102.17 1.02 5.75 101.58 
10.00 (HQC) 10.02 1.34 100.20 10.01 1.93 100.15 
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Table 5.2: In vitro microdialysis recovery factor of hesperidin, hesperetin and hesperidin-G at 
different perfusate (IPBS, pH 7.4) flow rates. The 3 µL/min was considered to be optimum, 
taking recovery factor and sample volume into consideration. Solution of these compounds was 
prepared in IPBS (pH 7.4) and to validate this, recovery was determined by adding these 
compounds to the vitreous humor, freshly obtained from male, New Zealand, white rabbits. 
Values represent mean ± SD (n=4). 
 
Medium Flow rate (µL/min) 
Recovery Factor 
Hesperidin Hesperetin Hesperidin-G 
IPBS (pH 7.4) 1.8 0.45 ± 0.05 0.39 ± 0.05 0.48 ± 0.05 
IPBS (pH 7.4) 3 0.37 ± 0.04 0.28 ± 0.03 0.39 ± 0.04 
Vitreous Humor 3 0.35 ± 0.05 0.25 ±  0.04 0.37 ±  0.06 
IPBS (pH 7.4) 4 0.28 ± 0.03 0.22 ± 0.04 0.30 ± 0.03 
 
 
Although the use of IPBS (pH 7.4) is well recognized as a substitute for the vitreous 
humor for characterizing the in vitro probe recovery factor, in our studies we further validated 
the in vitro microdialysis set up. Recovery was determined from the vitreous humor, spiked with 
hesperidin, hesperetin or hesperidin G (1 µg/mL final concentration). The recovery factor 
obtained from IPBS was found to be consistent with that obtained from the vitreous humor for all 
the three molecules (Table 5.2). Thus, IPBS was used for estimating the probe recovery factor, 
before and after each experiment, for each compound.  
Vitreal kinetics of hesperidin and hesperetin and a water soluble derivative of hesperidin, 
hesperidin G, were determined at three dose levels (1.5, 4.5 or 15 µg in 50 µL injection volume) 
following intravitreal administration in rabbits. The vitreal concentration-time profiles of 
hesperidin, hesperetin and hesperidin G at the three dose levels are presented in Figures 5.2, 5.3 
and 5.4, respectively.  
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Figure 5.2: Mean vitreal log concentration vs. time profile of hesperidin following intravitreal 
administration of hesperidin at three doses (1.5, 4.5 and 15 µg resulting in vitreal concentration 
of 1, 3 and 10 µg/mL, respectively). Injection volume was 50 µL. Values represent Mean ± SD 
(n=4). 
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Figure 5.3: Mean vitreal log concentration vs. time profile of hesperetin following intravitreal 
administration of hesperetin at three doses (1.5, 4.5 and 15 µg resulting in vitreal concentration 
of 1, 3 and 10 µg/mL, respectively). Injection volume was 50 µL. Values represent Mean ± SD 
(n=4). 
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Figure 5.4: Mean vitreal log concentration vs. time profile of hesperidin G following intravitreal 
administration of hesperidin G at three doses (1.5, 4.5 and 15 µg resulting in vitreal 
concentration of 1, 3 and 10 µg/mL, respectively). Injection volume was 50 µL. Values represent 
Mean ± SD (n=4). 
 
The vitreal concentration vs. time profile of hesperidin and hesperidin G suggested a two-
compartment pharmacokinetic model. Data was modeled according to one-compartment and 
two-compartment pharmacokinetic models. Akaike Information Criterion (AIC) and Schwarz 
Bayesian Criterion (SBC) were used for the selection of the most appropriate model, in addition 
to visual (graphical) estimation. Model selection criteria also indicated a two-compartment 
pharmacokinetic model for hesperidin and hesperidin G vitreal concentration-time profile, at all 
the dose levels tested. Thus, i.v. bolus two-compartment pharmacokinetic model was used for 
calculating the different pharmacokinetic parameters. However, in case of hesperetin, vitreal 
concentration vs. time profiles at the three doses suggested a one-compartment pharmacokinetic 
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model. Additionally, AIC and SBC criteria also confirmed one-compartment pharmacokinetic 
model as the best fit. Thus, i.v. bolus one-compartment pharmacokinetic model was used for 
calculating the pharmacokinetic parameters. Vitreal pharmacokinetic parameters of hesperidin, 
hesperetin and hesperidin G are presented in Tables 5.3, 5.4 and 5.5, respectively. 
 
 
Table 5.3: Calculated pharmacokinetic parameters of hesperidin at three doses (1.5, 4.5 and 15 
µg resulting in vitreal concentration of 1, 3 and 10 µg/mL, respectively) following intravitreal 
administration. Injection volume was 50 µL. Values represent mean (SD) (n=4). 
 
Parameter Units 
Intravitreal dose (µg) 
1.5 4.5 15 
AUC min.µg/mL 751 ± 88 1575 ± 164 4835 ± 861 
Cmax µg/mL 3.26 ± 1.35 10.82 ± 1.12 25.23 ± 3.02 
CL mL/min 0.0027 ± 0.0003 0.0029 ± 0.0003 0.0032 ± 0.0005 
CLD2 mL/min 0.0058 ± 0.0010 0.0054 ± 0.0026 0.0130 ± 0.0026 
Vss mL 1.48 ± 0.42 1.29 ± 0.21 2.07 ± 0.35 
V2 mL 0.75 ± 0.62 0.87 ± 0.21 1.46 ± 0.40 
Alpha 1/min 0.0267 ± 0.0077 0.0249 ± 0.0109 0.0358 ± 0.0084 
Beta 1/min 0.0016 ±0.0004 0.0017 ± 0.0003 0.0014 ± 0.0004 
Alpha_HL min 28 ± 7 31 ± 11 20 ± 5 
Beta_HL min 386 ± 116 407 ± 58 466 ± 98 
MRT min 545 ± 106 448 ± 55 668 ± 184 
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Table 5.4: Calculated pharmacokinetic parameters of hesperetin at three doses (1.5, 4.5 and 15 
µg resulting in vitreal concentration of 1, 3 and 10 µg/mL, respectively) following intravitreal 
administration. Injection volume was 50 µL. Values represent mean (SD) (n=4). 
 
Parameter Units 
Intravitreal dose (µg) 
1.5 4.5 15 
AUC min.µg/mL 179 ± 58 475 ± 70 1746 ± 146 
Cmax µg/mL 1.02 ± 0.20 4.51 ± 0.57 14.67 ± 1.99 
CL mL/min 0.0093 ± 0.0040 0.0096 ± 0.0015 0.0086 ± 0.00070 
VVH mL 1.52 ± 0.29 1.01 ± 0.13 1.04 ± 0.16 
T1/2 min 110 ± 28 89 ± 14 83 ± 10 
 
 
Table 5.5: Calculated pharmacokinetic parameters of hesperidin G at three doses (1.5, 4.5 and 
15 µg resulting in vitreal concentration of 1, 3 and 10 µg/mL, respectively) following intravitreal 
administration. Injection volume was 50 µL. Values represent mean (SD) (n=4). 
 
Parameter Units 
Intravitreal dose (µg) 
1.5 4.5 15 
AUC min.µg/mL 688 ± 47 1811 ± 269 6167 ± 168 
Cmax µg/mL 3.79 ± 1.06 20.16 ± 6.12 32.05 ± 4.39 
CL mL/min 0.0022 ± 0.0002 0.0025 ± 0.0004 0.0024 ± 0.0002 
CLD2 mL/min 0.011 ± 0.002 0.003 ± 0.001 0.007 ± 0.001 
Vss mL 1.41 ± 0.14 1.05 ± 0.013 1.25 ± 0.16 
V2 mL 1.00 ± 0.07 0.81 ± 0.05 0.78 ± 0.16 
Alpha 1/min 0.045 ± 0.019 0.028 ± 0.011 0.027 ± 0.007 
Beta 1/min 0.0014 ± 0.0002 0.0015 ± 0.0002 0.0017 ± 0.0003 
Alpha_HL min 17 ± 6 29 ± 16 27 ± 8 
Beta_HL min 495 ± 66 468 ± 82 414 ± 70 
MRT min 648 ± 90 418 ± 21 517 ± 80 
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Following intravitreal administration of a compound, it will be distributed within the 
vitreous humor and into the surrounding ocular tissues (retina, choroid, lens and aqueous humor), 
from where elimination may take place (140). Distribution of an intravitreally administered drug 
is governed by 1) the gel structure of the vitreous humor, 2) the time taken by the compound to 
set up equilibrium with the peripheral ocular tissues. The vitreous humor is composed of water 
(~ 98-99%) and solids (~ 1%, mainly collagen and glycosaminoglycans) (148). This solid 
content is responsible for maintaining the gel structure and acts as a molecular barrier to the 
diffusion of administered compounds with factors such as molecular weight and interactions 
between the drug and collagen through H-bonds for example, playing significant roles. 
Establishing of equilibrium between the peripheral ocular tissues and vitreous humor largely 
depends on the partition coefficient of the respective compounds (36). In our study hesperetin is 
observed to follow a one-compartment pharmacokinetic model (Fig. 5.3), indicating rapid 
distribution within the vitreous gel. Additionally, volume of the vitreous humor in the rabbits is 
around 1.5 mL and correspondingly, hesperetin volume of distribution (VVH) is in the range of 1 
– 1.5 mL (Table 3). The other two larger molecules with higher molecular weight, hesperidin and 
glucosyl hesperidin, exhibited a two-compartment pharmacokinetic model (Fig. 5.2 and 5.4), 
probably because of slower distribution within the vitreous humor and into peripheral ocular 
tissues (RCS, lens and aqueous humor). The Vss for these compounds is close to 1-2 mL and 
peripheral volume of distribution (V2) ranged between 075-1.5 mL. It was also reported that, 
distribution of large molecules depends on the convection, generated by pressure and 
temperature difference between anterior chamber and the retinal surface (36).  
It has been established that hepatic/intestinal beta-glucosidase and/or alpha-rhamnosidase 
converts hesperidin into hesperetin and hesperetin then undergoes phase-II metabolism to yield 
103 
 
hesperetin-glucoronides and hesperetin-sulphates. Additionally hesperetin can be converted into 
eriodictyol (9, 149, 150). In the case of hesperidin G, alpha-glucosidase converts hesperidin G 
into hesperidin. All these enzymes are reported to be present in the various ocular tissues, 
however, the expression levels are low compared to that present in the liver (151-153). In our 
study levels of metabolites, if any, following intravitreal administration of these compounds were 
not detected. This could be because of small sample volumes and/or low metabolite 
concentrations generated. In a majority of the cases, elimination of a drug molecule from the 
body has been assumed to follow first order kinetics. Nevertheless, it is also possible that 
elimination may display nonlinear pharmacokinetics. In such cases ‘concentration’ or 'dose' 
dependent kinetics are observed (154). In this study, all three compounds exhibited linear 
pharmacokinetics, within the dose range tested as indicated by a linear increase in the AUC and 
Cmax with administered dose (Fig. 5.5A and 5.5B) without a significant difference in the 
elimination parameters like clearance and elimination half-life across the doses (Tables 5.3, 5.4 
and 5.5).  
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Figure 5.5: Linear increase in vitreal pharmacokinetic parameters Cmax (A) AUC (B) following 
intravitreal administration of hesperidin, hesperetin, and hesperetin G at three doses. Values 
represent mean ± SD (n=4). 
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Elimination of intravitreally administered drug can take place by two major routes (36, 
139, 140). Direct pathway; the vitreous humor is enclosed by the retina, therefore the most direct 
pathway is through this tissue. The other route of elimination would be passage of the drug 
forward via the anterior elimination route through the aqueous humor (36). Taken together, the 
results of this study indicate that, among the three molecules, hesperetin is eliminated more 
rapidly, lowest elimination half-life (T1/2: 83.41 – 110.66 min) and highest clearance rate (CL: 
0.0086 - 0.0096 mL/min), from the vitreous humor, followed by hesperidin (T1/2: 385.68 – 
466.15 min; CL: 0.0027 - 0.0032 mL/min) and hesperidin G (T1/2: 413.83 – 495.07 min; CL: 
0.0024 - 0.0025 mL/min) (Tables 5.3, 5.4 and 5.5). This is probably because of higher 
lipophilicity (Log P: 2.9) and lower molecular weight (MW: 302.27) of hesperetin compared to 
hesperidin (Log P: 1.79; MW: 610.57) and hesperidin G (Log P: -3.2; MW: 772.70). Therefore, 
hesperetin can easily permeate across the retinal barrier. Furthermore, our previous in vitro 
permeation studies across isolated rabbit retina-choroid-sclera (RCS) indicated that the apparent 
permeability of hesperetin in the retina to scleral (R-S) direction (2.52 ± 0.51 X 10-6 cm/s) is 
higher compared to hesperidin (1.51 ± 0.78 X 10-6 cm/s) (132). The terminal elimination of a 
molecule from the vitreous humor is significantly dependent on the molecular weight (36). 
However, the difference between hesperidin and glucosyl hesperidin with respect to elimination 
half-life and clearance is not significant, indicating the role of H-bonding, polar surface area and 
other molecular characteristics on transretinal elimination.  
 The other important information that can be drawn from this study, from a drug delivery 
perspective, is that these compounds are exhibiting short half-life in the vitreous humor. Thus, in 
order to maintain the therapeutic levels for longer duration frequent administration would be 
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necessary. Thus, development of a sustained or controlled ocular drug delivery system is 
warranted. 
 
CONCLUSION  
Overall, in this study vitreal pharmacokinetics of hesperidin, hesperetin and hesperidin G 
were evaluated. All three molecules exhibit a linear vitreal pharmacokinetic profile within the 
dose range tested. Additionally, it was observed that vitreal kinetics of these molecules is 
dependent on their lipophilicity and molecular weight. The results provide practical information 
that will be useful in the future design of ocular drug delivery platforms for these molecules. 
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CHAPTER 6 : OCULAR DELIVERY OF HESPERIDIN AND 
HESPERETIN FOLLOWING INTRAVENOUS AND TOPICAL 
ADMINISTRATION 
 
ABSTRACT 
The objective of this study was to determine the ocular bioavailability of hesperidin and 
hesperetin following systemic and topical administration in rabbits. Microdialysis was employed 
to estimate the vitreal bioavailability and blood samples were collected to estimate systemic 
exposure. Vitreal samples did not demonstrate any detectable levels of hesperidin/hesperetin on 
intravenous administration. In the systemic circulation these compounds were rapidly 
metabolized into their glucuronides, which are extremely hydrophilic in nature. Considering the 
characteristics of the blood-retinal-barriers; very little, if any, of these hydrophilic metabolites 
can cross the ocular barrier to reach the vitreous humor. Following topical administration, 
concentrations of hesperidin/hesperetin were observed in all ocular tissues tested at 1 and 3 h 
post dosing, with hesperetin showing higher levels compared to hesperidin. However, very low 
levels were observed in the posterior segment. Inclusion of a penetration enhancer, 
benzalkonium chloride, improved the back-of-the eye hesperetin levels. Thus, in future studies 
penetration into the back-of-the eye with the aid of suitable formulation approaches is warranted. 
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INTRODUCTION  
Currently, hesperidin is used as a dietary supplement to improve blood flow and for its 
vasoprotective properties, and is available as an oral dosage form. Ameer et al., (155) reported 
that following oral administration, hesperidin is absorbed across the gastrointestinal tract, but 
cumulative urinary recovery indicates low bioavailability (< 25%). Several factors limit oral 
bioavailability of hesperidin, including poor water solubility and precipitation in an acidic 
environment.  
Drug delivery to the eye, in comparison to other parts of the body, poses significant 
challenges because of the presence of various barriers which are inherent and unique to the 
anatomy and physiology of the eye. The general routes of administration for ocular drug delivery 
include topical, periocular, intravitreal, systemic and oral routes.  A topically administered drug 
may penetrate into the posterior chamber tissues, such as the retina, through corneal or 
noncorneal routes (28). Transcorneal absorption represents the major route of penetration for 
most therapeutic agents. However, several studies demonstrate that the noncorneal route is also a 
significant route, wherein the drug molecule is supposed to penetrate into the intraocular tissues 
via diffusion across the conjunctiva and sclera (28, 156). For an orally administered drug, it has 
to first reach the systemic circulation and then into the eye. To move from the blood into the 
ocular tissue, the molecule needs to permeate across the blood-retinal barrier (BRB), formed by 
the retinal pigmented epithelium (RPE) and the endothelial cells of the retinal blood vessels. The 
diffusion limiting capabilities of the BRB has been well established for both hydrophilic (limited 
by tight junctions) as well as lipophilic (through efflux mechanism) compounds (157).  
The major goal of this project is to achieve therapeutically optimal hesperidin/hesperetin 
concentrations at the target site, i.e. posterior segment of the eye. Till now no one has 
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investigated the ocular bioavailability of hesperidin and its aglycone hesperetin through any 
route of administration. In this study, our major objective was to evaluate two routes of 
administration, systemic and topical, for the delivery of hesperidin and hesperetin to the posterior 
segment of the eye using the rabbit model. Additionally, the feasibility of the oral route for 
ocular delivery of the bioflavonoids may be judged from the results obtained from the 
intravenous administration study. Thus, the aim of this study was to determine plasma and vitreal 
kinetics of hesperidin and hesperetin following systemic and topical administration. The amount 
of the compounds reaching the posterior segment of the eye, especially vitreous humor, was 
monitored using vitreal microdialysis sampling technique.  
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MATERIALS AND METHODS 
Animals  
Studies were conducted using male New Zealand white rabbits, procured from Myrtle’s 
Rabbitry (Thompson Station, TN). Experiments conformed to the tenets of the Association for 
Research in Vision and Ophthalmology (ARVO) statement on the Use of Animals in Ophthalmic 
and Vision Research and followed the University of Mississippi Institutional Animal Care and 
Use Committee (IACUC) approved protocol (11-006). Each experiment was conducted at least 
in quadruplicates. 
Materials  
Hesperidin, hesperetin, beta-glucuronidase (Type HP-2, from Helix pomatia) and 
microsomes (obtained from rat liver, pooled) were purchased form Sigma-Aldrich (St. Louis, 
MO). Ketamine hydrochloride and xylazine were procured from Fort Dodge Animal Health (Fort 
Dodge, IA) and Lloyd Laboratories (Shenandoah, IA), respectively. Pentobarbital was obtained 
from Virbac AH, Inc. (Fort Worth, TX). Microdialysis probes (CMA/20; 20,000 Da molecular 
mass weight and 10 mm shaft) were obtained from CMA/Microdialysis Inc. (North Chelmsford, 
MA). All other chemicals and solvents (HPLC grade) used were purchased from Thermo Fisher 
Scientific (Waltham, MA) and used as such. 
In vitro Probe Recovery 
Microdialysis probe recovery was performed following a previously published report 
(44). Briefly, recovery values were determined by placing the probe in an isotonic phosphate-
buffered saline (IPBS) solution (pH 7.4) at 37 °C, containing a known concentration of the 
compound (hesperidin or hesperetin). The probe was perfused with sterile IPBS at a flow rate of 
111 
 
3 µL/min, and the dialysate was collected every 20 min. Relative recovery was calculated using 
eq. 1: 
Recoveryin vitro = Cd/Cs    (1) 
where Cd is the concentration of the respective compound in the dialysate and Cs is the 
concentration in IPBS. The concentration of the compounds in the vitreous humor samples was 
calculated by dividing the dialysate concentration by the respective, probe specific, in vitro 
recovery factor obtained as described above. The recovery of each probe was determined before 
and after each experiment. 
Intravenous Administration Study 
Probe Implantation: 
Probe were implanted following previously published reports (44). Briefly, rabbits 
(weighing 2–2.5 kg) were anesthetized using ketamine (35 mg/kg)/xylazine (3.5 mg/kg) 
administered intramuscularly, and were maintained under anesthesia throughout the duration of 
the experiment (ketamine/xylazine administered intramuscularly every 40 min). Before probe 
implantation, 1% tropicamide was applied topically to dilate the pupil. A 22-guage needle was 
then inserted into the posterior chamber of the eye. The point of insertion was approximately 3 
mm below the corneal-scleral limbus. The needle was withdrawn and the vitreal probe was 
implanted immediately. The position of the probe was adjusted so that the semipermeable 
membrane was in the mid-vitreous section. The probes were continuously perfused with sterile 
IPBS (pH 7.4) at a flow rate of 3 µL/min using a CMA/100 microinjection pump 
(CMA/Microdialysis Inc.). After probe implantation, animals were allowed to stabilize for a 
period of 2 h before the administration of the respective compounds. Vitreal samples were 
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collected every 20 min for a period of 10 h. Samples were collected in microcentrifuge tubes and 
stored at -80°C until further analysis. At the end of the study, animals were euthanized, under 
deep anesthesia, with an overdose of sodium pentobarbital administered through the marginal ear 
vein. 
Intravenous Administration of hesperidin/hesperetin:  
After anaesthetizing the rabbits, a 21–25 gauge catheter was placed in the central ear 
artery for plasma sampling. Once the catheter was placed appropriately, heparin solution was 
injected into the catheter to prevent clotting of the line. Subsequently, the microdialysis probe 
was implanted and following its stabilization period 0.5 mL of hesperidin or hesperetin solution, 
formulated in dimethyl sulfoxide : propylene glycol: IPBS (pH7.4) (40:40:20), was administered 
intravenously through the marginal ear vein (20 mg/kg BW). Four animals were studied for each 
compound. Blood samples were withdrawn and then collected in heparinized vials at 
approximately 0, 10, 15, 30, 60, 90, 120, 240, 360 and 480 min post dosing. Plasma was 
separated from the whole blood by centrifugation at 13,000 rpm for 10 min at 4 ºC (accuSpin 
Micro 17R, Thermo Fisher Scientific (Waltham, MA, USA)) and was stored at -80 ºC until 
further analysis. 
Topical Administration Study:  
In our previous studies we found that these compounds were highly insoluble in water 
(118, 132). Thus, hesperidin solution (1 % w/v) for topical instillation was prepared by 
dissolving it in 100 µL of 1 N sodium hydroxide and adding this solution to 10 % HP-β-CD 
(prepared in IPBS, pH 7.4, containing 0.1 % HPMC). Final pH was adjusted to 7.4 using 1 N 
hydrochloric acid. The hesperetin solution was prepared by dissolving it  in 100 µL of 1 N 
sodium hydroxide and adding this solution to 10 % HP-β-CD or 10 % RM-β-CD (prepared in 
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IPBS, pH 7.4, containing 0.1 % HPMC) and the final pH was adjusted to 7.4 using 1 N 
hydrochloric acid. In the case of hesperetin an additional solution formulation, which included 
0.05% benzalkonium chloride (BAK), was also tested.  
Rabbits were anaesthetized as described in the microdialysis probe implantation section 
and were maintained under anesthesia throughout the duration of the experiment. Following 
anesthesia, hesperidin or hesperetin solution (100 µL of 1 % w/v) was administered topically into 
the cul-de-sac of one eye of the rabbit and held for 30 sec. Later, rabbits were sacrificed at 1 and 
3 h post dosing, eyes were collected and ocular tissues (cornea, iris-ciliary body, lens, retina-
choroid, sclera, aqueous humor and vitreous humor) were isolated, weighed and stored at -80 °C 
until further analysis. 
Analytical Methods 
Liquid Chromatography/Mass spectrometry (LC-ESI-TOF): 
The liquid chromatography system used was an Agilent Series 1100 comprising of the 
following modular components: quaternary pump, a vacuum solvent microdegasser, an 
autosampler with 100-well tray. The mass spectrometric analysis was performed by using the 
LC-ESI-TOF (Model #G1969A, Agilent Technologies, Palo Alto, CA, USA) equipped with an 
ESI source. All acquisitions were performed under positive ionization mode with a capillary 
voltage of  3000 V. Nitrogen was used as the nebulizer gas (35 psig) as well as the drying gas at 
11 L/min at a temperature of 350 ºC. The voltage of PMT, fragmentor and skimmer was set at 
850V, 100V and 60V respectively. Full scan mass spectra were acquired from m/z 200-1000. 
Data acquisition and processing was done using the AnalystTM QS software (Agilent 
Technologies, Palo Alto, CA, USA).  
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Chromatographic separation was achieved on a synergi Hydro-RP; 100 x 2.0 mm I.D.; 4 
µm particle size (Phenomenex, Torrance, CA, USA).  The column was equipped with a guard 
column (Supelco, Bellefonte, PA, USA).  The mobile phase consisted of ammonium formate (20 
mM) with 0.1 % formic acid (A), and acetonitrile with 0.1 % formic acid (B) at a flow rate of 0.3 
mL/min, with the following gradient elution: 0 min, 95 % A/5 % B to 100 % B over 10 min. 
Each run was followed by a 5 min wash with 100 % B and an equilibration period of 11 min with 
95 % A/5 % B. The total run time for analysis was 10 minutes. Sample (10 µL) was injected and 
peaks were assigned with respect to the mass of the compounds and comparison of the retention 
times. This method involved the use of the [M+H]+ ions in the positive ion mode with extractive 
ion monitoring (EIM). In the positive ion mode, the protonated species [M+H]+ at m/z 611. 1991 
for hesperidin, 303.0869 for hesperetin and 581.19 for naringin (internal standard) were observed 
(Fig 6.1). 
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Figure 6.1: Selected ion chromatogram and mass spectra of standard compounds (1 µg/mL) 
 
Plasma Sample Analysis:  
Hesperidin and hesperetin have been previously reported to undergo Phase-II metabolism 
to form hesperetin-glucuronide (158, 159). However, hesperetin-glucuronide standard is 
commercially not available; therefore the plasma samples were run in duplicates with and 
without the addition of 40 µL of 15,000 units/mL of beta-glucuronidase (HP-2 type solution 
from Helix Pomatia) in 0.1 mM acetate buffer (pH 5.0). Following the addition of the beta-
glucuronidase, samples were incubated at 37 °C for 2 h, to convert the conjugated metabolite to 
parent hesperetin. Later, 30 µL of internal standard (naringin 10 µg/mL) was added to both 
samples and mixed thoroughly. To this mixture 330 µL of acetonitrile:methanol (50:50) was 
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added to precipitate the proteins and centrifuged (accuSpin micro 17R, Thermo Fisher Scientific) 
at 12,000 rpm for 20 min at 4 °C. Supernatant was collected and analyzed for the 
hesperidin/hesperetin using LC-MS. Calibration standards (1-1000 ng/mL) were prepared by 
spiking known amount of hesperidin/hesperetin, with internal standard, into blank rabbit plasma. 
Ocular Tissue Sample Analysis: 
 To a weighed quantity of the respective ocular tissue (cornea, iris-ciliary, lens, sclera, 
choroid-retina) 60 µL of the internal standard (naringin 10 µg/ mL) was added and mixed 
thoroughly. To this, 3 mL of acetonitrile:methanol (50:50) mixture was added and homogenized 
using a Tissuemiser (Thermo Fisher Scientific). The homogenate was centrifuged (accuSpin 
micro 17R, Thermo Fisher Scientific) at 12,000 rpm for 20 min at 4 °C. Supernatant was 
collected and analyzed for content using LC-MS. Calibration standards (1-1000 ng/mL) were 
prepared by spiking a known amount of hesperidin/hesperetin, with internal standard, into 
respective blank rabbit ocular tissue homogenate. 
Microdialysis Sample Analysis: 
 Hesperidin and hesperetin content in the microdialysis samples obtained from the 
intravenous administration study was analyzed using an HPLC method. An HPLC system 
equipped with Waters 600 pump controller, 2470 dual wavelength UV detector, refrigerated 717 
plus auto-sampler and Agilent 3394B integrator was used. The detector was operated at 284 nm. 
Mobile phase consisted of 20 mM monobasic potassium phosphate (pH adjusted to 2.5 with 
ortho-phosphoric acid) and acetonitrile in a ratio of 75:25 and 50:50 for hesperidin and 
hesperetin, respectively. The flow rate was maintained at 1 mL/min. A Phenomenex Luna, 250 X 
4.6 mm, 5µ, C18(2) column was used. Samples were injected (30 µL) on to the column as such. 
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Calibration standards were in the range of 0.02 - 15.0 µg/mL for hesperetin and 0.05 - 15.0 
µg/mL for hesperidin. 
Data Analysis 
Pharmacokinetic parameters were determined using WinNonlin® (version 5.2; Pharsight, 
Mountain View, CA). Terminal slopes of the vitreous concentration-time profile were estimated 
by log-linear regression, and the apparent elimination rate constant (k) was derived from the 
slope. Elimination half-life (t1/2) was calculated from the equation  
t1/2 = 0.693/k.  
The area under the vitreal concentration-time curve from time 0 to time t was calculated 
by the linear trapezoidal method and extrapolated to infinity according to eq. 2: 
AUC(0-α)= AUC(0-t)+(Clast/k) 
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RESULTS 
Intravenous Administration: 
Hesperidin and hesperetin are reported to form hesperetin-glucuronide in vivo and we 
wanted to estimate the concentration of this metabolite in the plasma samples. However, 
hesperetin-glucuronide standard is commercially not available, thus experimental conditions for 
the conversion of hesperetin-glucuronide in the plasma to hesperetin with the aid of the de-
conjugating enzyme, beta-glucuronidase, were optimized. For this, hesperetin-glucuronides were 
initially formed using rat liver microsomes. Formation of the glucuronides and their conversion 
to hesperetin was confirmed analytically. A similar procedure has been adapted for the 
estimation of hesperetin-glucuronide content in the plasma samples in several other reports (160, 
161). 
Hesperidin Systemic Pharmacokinetics: Hesperidin was administered intravenously at a dose 
of 20 mg/Kg BW to anesthetized rabbits. Plasma samples without beta-glucuronidase treatment 
did not show any levels of hesperetin. Only hesperidin levels were observed in these samples. 
However, plasma samples treated with the beta-glucuronidase enzyme exhibited levels of 
hesperetin along with the parent hesperidin. This indicates that, following systemic 
administration, hesperidin exists in the plasma as the parent hesperidin and as its Phase-II 
metabolite, hesperetin-glucuronide. It should be noted that the hesperetin levels obtained in the 
enzyme treated plasma samples actually represents the levels of the metabolite, hesperetin-
glucuronide. 
Observed plasma concentration-time profiles of hesperidin and the metabolite hesperetin-
glucuronide (estimated in the plasma as hesperetin) is presented in Figure 6.2. Systemic 
pharmacokinetic parameters of hesperidin and regenerated hesperetin were calculated using non-
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compartmental analysis (NCA) and have been presented in Table 6.1. It is apparent from the 
observed results that, hesperidin’s plasma half-life (6.74 h) is relatively short and that the plasma 
levels decrease rapidly. The metabolite, hesperetin-glucuronide, also demonstrated a very short 
half-life, around 5.16 h. Systemic clearance of hesperidin was found to be 6.69 ± 0.58 L/h/Kg. 
 
 
 
Figure 6.2: Mean plasma concentration-time profile of hesperidin and hesperetin-glucuronide 
(estimated as hesperetin after the treatment of the plasma samples with beta-glucuronidase to 
convert hesperetin-glucuronide to hesperetin), generated in vivo, in the rabbits following 
intravenous administration of hesperidin at 20 mg/Kg body weight (N=4). 
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Table 6.1: Calculated pharmacokinetic parameters from the plasma concentration-time profile of 
hesperidin and hesperetin-glucuronide (estimated as hesperetin after the treatment of the plasma 
samples with beta-glucuronidase to convert hesperetin-glucuronide to hesperetin), following 
intravenous administration of hesperidin at 20 mg/Kg. Non-compartmental analysis was 
followed for calculating PK parameters. Values represent mean ± SD (N=4) 
 
PK Parameter Hesperidin  Hesperetin-glucuronide  
Half-life (h)  6.74 ± 0.79 5.16 ± 1.56 
C0 (ng/mL)  4559 ± 1004 
 
AUC last (h.ng/mL)  2516 ± 157 1205 ± 132 
AUC inf (h.ng/mL)  3004 ± 236 1382 ± 135 
Vd (L/Kg)  64.58 ± 3.70 
 
CL (L/h/Kg)  6.69 ± 0.58 
 
MRT (h)  4.22 ± 0.67 3.63 ± 1.27 
 
 
Hesperetin Systemic Pharmacokinetics 
Hesperetin was administered intravenously at a dose of 20 mg/Kg to the anesthetized 
rabbits. Blood samples were collected to estimate the systemic availability of hesperetin and its 
metabolite, hesperetin-glucuronide. The first set of plasma samples that were analyzed directly, 
without treatment with the beta-glucuronidase enzyme, showed hesperetin concentrations. The 
hesperetin concentrations in the second set, where the plasma samples were treated with the beta-
glucuronidase enzyme, were significantly higher compared to first sample set. This suggests that 
hesperetin undergoes metabolism in vivo and forms hesperetin-glucuronide. Thus, on treating 
these plasma samples with the beta-glucuronidase enzyme, higher levels of hesperetin were 
observed.  To get the concentration of the metabolite, hesperetin-glucuronide, concentration of 
hesperetin in first set of samples were subtracted from the second set. The plasma concentration-
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time profile of hesperetin and its metabolite, hesperetin-glucuronide is presented in Figure 6.3. 
Pharmacokinetic parameters were calculated using non-compartmental analysis and have been 
presented in Table 6.2. The biological half-life (4.6 h) and MRT (3.17 h) of the metabolite, 
hesperetin-glucuronide, was found to be similar to that observed upon hesperidin administration 
(5.16 and 3.63 h, respectively).  
 
 
 
Figure 6.3: Mean plasma concentration-time profile of hesperetin (from direct analysis) and 
hesperetin-glucuronide (estimated as hesperetin after the treatment of the plasma samples with 
beta-glucuronidase to convert hesperetin-glucuronide to hesperetin) following intravenous 
administration of hesperetin at a dose of 20 mg/Kg in rabbits (N=4). 
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Table 6.2: Calculated pharmacokinetic parameters from plasma concentration-time profile of 
hesperetin (from direct analysis) and hesperetin-glucuronide (estimated as hesperetin after the 
treatment of the plasma samples with beta-glucuronidase to convert hesperetin-glucuronide to 
hesperetin) following intravenous administration of hesperetin at 20 mg/Kg. Non-compartmental 
analysis was followed for calculating PK parameters. Values represent mean ± SD (N=4). 
 
PK Parameter Hesperetin Hesperetin-glucuronide 
Half-life (h)  5.32 ± 0.62  4.61 ± 0.62  
C0 (ng/mL)  2220  ± 518    
AUClast (h.ng/mL)  906  ± 89  1648 ± 418  
AUCinf (h.ng/mL)  1055  ± 111  1855 ± 513  
Vd (L/Kg)  145.60  ± 8.84    
CL (L/h/Kg)  19.09  ± 1.99    
MRT (h)  3.60 ± 0.21  3.17 ± 0.39  
 
Vitreal Bioavailability: 
 Vitreal microdialysis was carried out to estimate the amount of hesperidin or hesperetin 
reaching the vitreous humor following intravenous administration. However, these samples did 
not exhibit any detectable levels of the compounds, indicating that their vitreal bioavailability is 
negligible through systemic route. 
Topical Administration:  
Experiments were carried out in anesthetized rabbits and the eyes were collected at 1 and 
3 h post administration. The ocular tissues were isolated and analyzed for hesperidin or 
hesperetin. Levels of hesperidin and hesperetin observed in the ocular tissues following topical 
administration are presented in Fig 6.4. and Fig 6.5., respectively. Hesperidin and hesperetin 
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levels were observed in all the ocular tissues tested. However, low concentrations were observed 
in the retina-choroid and vitreous humor, the targeted sites.  
In another set of studies, effect of the solubilizers (HP-β-CD and RM-β-CD) and 
penetration enhancer/preservative (benzalkonium chloride (BAK)) on hesperetin’s ocular 
penetration following topical administration was studied. The results from these experiments 
have been presented in Table 6.3 and 6.4. Hesperetin concentrations achieved in the retina with 
HP-β-CD (2.62 µg/g of tissue) was not significantly different from that observed with RM-β-CD 
(2.5 µg/g of tissue) based formulations. However, higher hesperetin levels were obtained in the 
vitreous humor with HP-β-CD compared to RM-β-CD. The effect of BAK was more pronounced 
in the presence of HP-β-CD rather than RM-β-CD. 
 
Figure 6.4: Levels of hesperidin observed in the rabbit ocular tissues at 1 h and 3 h following 
topical administration of hesperidin (100 µL of 1 % w/v solution containing HP-β-CD (10 % 
w/v), HPMC (0.1 % w/v), 1 N NaOH (0.05 % v/v) and 1 N HCl (0.05 % w/v) IPBS pH 7.4 
(q.s.)). Values represent mean ± SD (N=4). 
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Figure 6.5: Levels of hesperetin observed in the rabbit ocular tissues at 1 h and 3 h following 
topical administration of hesperetin (100 µL of 1 %w/v solution containing HP-β-CD (10 % 
w/v), HPMC (0.1 % w/v), 1 N NaOH (0.05 % v/v) and 1 N HCl (0.05 % w/v) IPBS pH 7.4 
(q.s.)). Values represent mean ± SD (N=4). Values represent mean ± SD (N=4). 
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Table 6.3: Hesperetin concentrations observed in the rabbit ocular tissues at 1 h following 
topical administration of 100 µL of hesperetin solution (1 %w/v) containing HP-β-CD (10 % 
w/v), HPMC (0.1 % w/v), 1 N NaOH (0.05 % v/v), 1 N HCl (0.05 % w/v), benzalkonium 
chloride (BAK) (0 or 0.05 % w/v) IPBS pH 7.4 (q.s.). Values represent mean ± SD (N=4). 
 
  
HP-β-CD HP-β-CD : BAK  Fold difference 
Aqueous Humor 0.84 ± 0.21  1.06 ± 0.21 1.26 
Vitreous Humor 0.016 ± .01 0.15 ± 0.03 9.62 
Cornea 15.53 ± 8.15 27.05 ± 6.53 1.74 
Iris-ciliary 12.61 ± 8.21  27.10 ± 13.61 2.15 
Retina 2.62 ± 0.81 18.39 ± 4.86 7.01 
Sclera 4.66 ± 2.29 10.25 ± 3.78 2.20 
 
 
Table 6.4: Hesperetin concentrations observed in the rabbit ocular tissues at 1 h following 
topical administration of 100 µL of hesperetin solution (1 %w/v) containing RM-β-CD (10 % 
w/v), HPMC (0.1 % w/v), 1 N NaOH (0.05 % v/v), 1 N HCl (0.05 % w/v), benzalkonium 
chloride (BAK) (0 or 0.05 % w/v) and IPBS pH 7.4 (q.s.). Values represent mean ± SD (N=4). 
 
  RM-β-CD RM-β-CD:BAK  Fold difference 
Aqueous Humor 0.06 ± 0.03  0.23 ± 0.14 3.59 
Vitreous Humor 0.06 ± 0.02 0.14 ± 0.02 2.47 
Cornea 5.13 ± 1.86 17.62 ± 7.07 3.02 
Iris-ciliary 3.46 ± 2.32 6.40 ± 2.16 2.46 
Retina 2.50 ± 1.04 5.62 ± 0.15 2.78 
Sclera 1.32 ± 0.56 5.42 ± 1.17 4.80 
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DISCUSSION 
Drug delivery to the deeper ocular tissues poses significant challenges because of the 
presence of various barriers. In this current investigation, hesperidin and hesperetin delivery to 
the posterior segment of the eye was determined following systemic and topical administration, 
in anesthetized rabbits. 
Intravenous Administration: 
Upon systemic administration, therapeutic agents could reach the posterior segment of 
the eye; however, molecules encounter the BRB comprised of the endothelial cells of the retinal 
capillaries and the epithelial cells of the RPE. The BRB acts as a significant diffusional barrier, a 
characteristic dependent on the physiochemical properties of the diffusing molecule and its 
interaction with different influx and efflux transporters expressed on the BRB. It is generally 
believed that the BRB favors diffusion of lipophilic molecules (157). 
Vitreal microdialysis was carried out to measure the amount of the compound reaching 
the vitreous humor following systemic administration. Blood samples were also collected, from 
the same rabbits, to measure the systemic exposure of hesperidin/hesperetin and its metabolite. 
The phase-II metabolism is the major pathway responsible for the intestinal and hepatic 
metabolism of hesperidin, wherein hesperidin is converted to hesperetin and hesperetin then 
undergoes glucuronidation (155), which is the major circulating metabolite. Thus, in order to 
evaluate the systemic availability, concentrations of both hesperidin/hesperetin and hesperetin-
glucuronide were measured. Hesperetin-glucuronide concentrations were obtained following 
treatment of the plasma samples with beta-glucuronidase to convert it into hesperetin and the 
hesperetin levels were then estimated.  
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Surprisingly, hesperidin was not detected in the microdialysis samples collected from the 
vitreous humor. This could be attributed to several factors. First, in general, ocular 
bioavailability from the systemic circulation is limited by the BRB. The barrier property of the 
BRB is such that passage of hydrophilic molecules is very limited (162, 163). Since, hesperidin 
undergoes rapid systemic metabolism to its hydrophilic metabolite (Fig 6.2), diffusion across the 
BRB would be severely restricted. Moreover, the extrapolated mean concentration of hesperidin 
at time zero, the maximum concentration following intravenous administration, is around 4.5 
µg/mL (Table 6.1). Considering hesperidin’s in vitro permeability (0.82 X 10-6 cm/sec) across 
the sclera-choroid-RPE (118), which is an underestimation of the actual in vivo barrier 
characteristics, very little, if any, hesperidin levels would be expected in the vitreous humor. 
Estimation of these low concentrations might also be limited by the microdialysis recovery factor 
In the case of hesperetin, a better permeation across the BRB can be expected, since 
hesperetin is more lipophilic (LogP 2.9) compared to that of hesperidin (LogP 1.78). This is also 
suggested by its greater in vitro permeability (2.37 X 10-6 cm/sec) across the sclera-choroid-RPE 
compared to that of hesperidin’s (0.82 X 10-6 cm/sec). Additionally, in our previous study with 
quinidine, having a similar LogP (2.6) and molecular weight (324.417 g/mole), respectable levels 
were observed in the vitreous humor upon systemic administration (141). However, in this study, 
vitreal samples failed to exhibit any detectable levels of hesperetin. This can be attributed to 
several factors. It is apparent from the plasma concentration-time profile of hesperetin that high 
plasma hesperetin concentrations are not maintained long enough to drive permeation across the 
BRB into the vitreous humor. Again, this could be because of rapid in vivo metabolism of 
hesperetin into its glucuronide (Fig. 6.3), which is highly hydrophilic in nature. Therefore, 
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permeation of these hydrophilic molecules across the BRB is a limiting factor. It is thus not 
surprising that hesperetin concentrations were not detectable in the vitreous humor.  
Topical Administration: 
Since, in this study, hesperidin and hesperetin are being targeted to the posterior segment 
of the eye, penetration of these compounds into the ocular tissues following topical 
administration was estimated in the anesthetized rabbits. Effective concentrations of hesperidin 
and hesperetin needed for various pharmacological activities have been reported by several 
researchers. These compounds exhibited dose dependent activities in different in vitro (1-100 
µM) (60, 72, 85, 91, 142-144) and in vivo studies (10-80 mg/Kg BW). Additionally, several 
studies indicate that hesperetin is more potent compared to hesperidin (92, 120, 145-147).  
Results from the topical administration studies with hesperidin and hesperetin in the 
rabbits (Fig 6.4 and 6.5) indicate that higher levels were observed in the cornea, sclera, iris-
ciliary body and aqueous humor for both compounds, consistent with the corneal penetration 
pathway. With regard to the posterior segment of the eye (choroid-retina and vitreous humor), 
higher concentrations were evident in the choroid-retina in comparison to the vitreous humor. 
However, from a therapeutic standpoint, levels of these compounds declined rapidly from almost 
all the tissues. For example, in the choroid-retina there was more than 50 % decrease in 
concentration within 2 h. From these results and from our previous in vitro ocular permeability 
studies, it is apparent that the sclera is not a big barrier and that these compounds are able to 
reach the choroid-retina. However, they are not able to efficiently permeate across the BRB.  
Comparing the levels of hesperidin and hesperetin obtained in the ocular tissues tested, it 
was evident that hesperetin demonstrated greater in vivo permeability (Fig 6.4 and 6.5). This 
could be because of physicochemical properties of the administered compound. It is well 
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recognized that corneal and choroid-retina transport favors relatively lipophilic molecules. In this 
case, hesperetin is more lipophilic (Log P 2.9) compared to hesperidin (Log P 1.78). 
Additionally, the molecular size of hesperetin is much smaller compared to hesperidin. These 
factors explain the better in vivo permeability of hesperetin. 
However, the vitreal levels achieved even with hesperetin is sub-therapeutic. To improve 
penetration into the deeper ocular tissues, effect of solubilizers and BAK (as the penetration 
enhancer) in the topical formulation was studied (Table 6.3 and 6.4). Cyclodextrins are a group 
of cyclic oligosaccharides that have been shown to improve solubility of a multitude of poorly 
soluble compounds, through the formation of inclusion complexes. Several reviews have been 
published on the applications of cyclodextrins in ocular drug delivery (104, 164). In this study, 
hesperetin concentrations achieved in the vitreous humor and the choroid-retina were similar 
from HP-β-CD and RM-β-CD based formulations. However, HP-β-CD produced higher levels in 
the anterior segment of the eye. BAK has often been investigated as penetration enhancer in 
ocular preparations in several studies (165-168). It is believed that BAK improves drug penetration 
by acting primarily on the tight junctions. In a study by Okabe et al., 0.05 % of BAK had produced 
no substantial histological and electrophysiological changes in the eye and improved the 
penetration of tested compounds (165). In this study, inclusion of BAK in the HP-β-CD and RM-
β-CD based formulations improved the penetration of hesperetin into the ocular tissues. 
Additionally, BAK was observed to be more effective when combined with HP-β-CD rather than 
RM-β-CD in terms of fold-increase in hesperetin concentrations generated in the retina-choroid 
and the vitreous humor. 
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CONCLUSIONS  
In conclusion, ocular bioavailability of hesperidin or hesperetin is negligible following 
intravenous administration. This could be primarily because of the metabolism of these 
compounds into their more hydrophilic derivatives. Based on the intravenous administration 
study results, it can be concluded that the ability of these compounds to reach the deeper ocular 
tissues following oral administration, considering the high intestinal and hepatic metabolism, 
will be very poor. On the other hand, following topical administration significant concentrations 
of hesperidin and hesperetin were observed in the ocular tissues. However, very low levels were 
evident in the posterior segment ocular tissues tested. Inclusion of the penetration enhancer, 
benzalkonium chloride, improved the hesperetin levels in the back-of-the eye tissues. Thus, 
further studies attempting to improve penetration into the back-of-the eye, through the topical 
administration route, with the aid of formulation approaches is warranted. 
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